IL291890A - 18-mc for treatment of substance use disorders - Google Patents
18-mc for treatment of substance use disordersInfo
- Publication number
- IL291890A IL291890A IL291890A IL29189022A IL291890A IL 291890 A IL291890 A IL 291890A IL 291890 A IL291890 A IL 291890A IL 29189022 A IL29189022 A IL 29189022A IL 291890 A IL291890 A IL 291890A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- day
- hci
- administering
- individual
- Prior art date
Links
- 208000011117 substance-related disease Diseases 0.000 title claims description 28
- 238000011282 treatment Methods 0.000 title description 40
- DTJQBBHYRQYDEG-SVBQBFEESA-N 18-methoxycoronaridine Chemical class C([C@@H]1C[C@@H]([C@H]2[C@]3(C1)C(=O)OC)CCOC)N2CCC1=C3NC2=CC=CC=C12 DTJQBBHYRQYDEG-SVBQBFEESA-N 0.000 claims description 415
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 102
- 230000000694 effects Effects 0.000 claims description 86
- 239000002207 metabolite Substances 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 78
- 241000700159 Rattus Species 0.000 claims description 72
- 229960003920 cocaine Drugs 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 42
- 239000000126 substance Substances 0.000 claims description 28
- 238000003556 assay Methods 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 19
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 19
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 19
- 239000003937 drug carrier Substances 0.000 claims description 17
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 16
- 230000036982 action potential Effects 0.000 claims description 15
- 235000019788 craving Nutrition 0.000 claims description 14
- 201000009032 substance abuse Diseases 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000037361 pathway Effects 0.000 claims description 11
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 10
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 claims description 10
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims description 10
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims description 10
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 claims description 10
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims description 10
- 229960002715 nicotine Drugs 0.000 claims description 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 10
- -1 opiates Chemical compound 0.000 claims description 10
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 9
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims description 9
- 210000004727 amygdala Anatomy 0.000 claims description 9
- 229960001252 methamphetamine Drugs 0.000 claims description 9
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 9
- 210000003742 purkinje fiber Anatomy 0.000 claims description 9
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims description 8
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 8
- 229960005181 morphine Drugs 0.000 claims description 8
- 229940127240 opiate Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000000747 cardiac effect Effects 0.000 claims description 7
- 231100000736 substance abuse Toxicity 0.000 claims description 7
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 6
- 230000003014 reinforcing effect Effects 0.000 claims description 6
- 229930182851 human metabolite Natural products 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 6
- 102000034337 acetylcholine receptors Human genes 0.000 claims 2
- 241001465754 Metazoa Species 0.000 description 100
- 238000012360 testing method Methods 0.000 description 82
- 229940079593 drug Drugs 0.000 description 64
- 239000003814 drug Substances 0.000 description 64
- 239000003981 vehicle Substances 0.000 description 45
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 41
- 229960004373 acetylcholine Drugs 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 39
- 230000004044 response Effects 0.000 description 37
- 230000001965 increasing effect Effects 0.000 description 30
- 230000003247 decreasing effect Effects 0.000 description 27
- 241000282693 Cercopithecidae Species 0.000 description 24
- 230000036760 body temperature Effects 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 230000034994 death Effects 0.000 description 23
- 231100000517 death Toxicity 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 23
- 230000036470 plasma concentration Effects 0.000 description 23
- 230000006399 behavior Effects 0.000 description 22
- 210000001185 bone marrow Anatomy 0.000 description 22
- 230000007423 decrease Effects 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 21
- 230000004913 activation Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 230000002503 metabolic effect Effects 0.000 description 19
- 230000000763 evoking effect Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 238000011084 recovery Methods 0.000 description 17
- 238000011887 Necropsy Methods 0.000 description 16
- 238000013103 analytical ultracentrifugation Methods 0.000 description 16
- 230000002411 adverse Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- 230000008030 elimination Effects 0.000 description 14
- 238000003379 elimination reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000004075 alteration Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 231100000027 toxicology Toxicity 0.000 description 12
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 210000001541 thymus gland Anatomy 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 231100000041 toxicology testing Toxicity 0.000 description 10
- 208000031404 Chromosome Aberrations Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 231100000005 chromosome aberration Toxicity 0.000 description 9
- 239000008121 dextrose Substances 0.000 description 9
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 231100000607 toxicokinetics Toxicity 0.000 description 9
- 230000003542 behavioural effect Effects 0.000 description 8
- 238000003927 comet assay Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000003188 neurobehavioral effect Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- 229960003638 dopamine Drugs 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 231100000706 no observed effect level Toxicity 0.000 description 7
- 238000003305 oral gavage Methods 0.000 description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000001174 ascending effect Effects 0.000 description 6
- 231100000170 comet assay Toxicity 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000003291 dopaminomimetic effect Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 5
- 206010017577 Gait disturbance Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 210000000748 cardiovascular system Anatomy 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 230000017858 demethylation Effects 0.000 description 5
- 238000010520 demethylation reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 231100000025 genetic toxicology Toxicity 0.000 description 5
- 230000001738 genotoxic effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000007171 neuropathology Effects 0.000 description 5
- 231100001160 nonlethal Toxicity 0.000 description 5
- 210000001009 nucleus accumben Anatomy 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- NVVDQMVGALBDGE-PZXGUROGSA-N (-)-coronaridine Chemical compound C([C@@H]1C[C@@H]([C@H]2[C@]3(C1)C(=O)OC)CC)N2CCC1=C3NC2=CC=CC=C12 NVVDQMVGALBDGE-PZXGUROGSA-N 0.000 description 4
- 241001463143 Auca Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 102000009660 Cholinergic Receptors Human genes 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 206010011906 Death Diseases 0.000 description 4
- 206010013654 Drug abuse Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001800 adrenalinergic effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 206010013663 drug dependence Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000033444 hydroxylation Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 230000002787 reinforcement Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000013222 sprague-dawley male rat Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000002110 toxicologic effect Effects 0.000 description 4
- 238000002562 urinalysis Methods 0.000 description 4
- 208000019206 urinary tract infection Diseases 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 231100000039 Ames test Toxicity 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 108090000312 Calcium Channels Proteins 0.000 description 3
- 102000003922 Calcium Channels Human genes 0.000 description 3
- 206010053398 Clonic convulsion Diseases 0.000 description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004245 medial forebrain bundle Anatomy 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 3
- 238000007431 microscopic evaluation Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 3
- 238000010984 neurological examination Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 101150005573 uvrA gene Proteins 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- ARLKVQYMFRECLV-JSGCOSHPSA-N (2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanamide Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(N)=O)=CNC2=C1 ARLKVQYMFRECLV-JSGCOSHPSA-N 0.000 description 2
- CVBFKKVQGICEBT-BWXWGAIDSA-N 18-methoxycoronaridine hydrochloride Chemical compound Cl.C([C@@H]1C[C@@H]([C@H]2[C@]3(C1)C(=O)OC)CCOC)N2CCC1=C3NC2=CC=CC=C12 CVBFKKVQGICEBT-BWXWGAIDSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 238000010953 Ames test Methods 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102100021752 Corticoliberin Human genes 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010011953 Decreased activity Diseases 0.000 description 2
- NVVDQMVGALBDGE-UHFFFAOYSA-N Dihydrocatharanthin Natural products C1C2(C(=O)OC)C3C(CC)CC1CN3CCC1=C2NC2=CC=CC=C12 NVVDQMVGALBDGE-UHFFFAOYSA-N 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 238000010167 Fisher's least significant difference multiple comparison test Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 206010001584 alcohol abuse Diseases 0.000 description 2
- 208000025746 alcohol use disease Diseases 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 230000009084 cardiovascular function Effects 0.000 description 2
- GKWYINOZGDHWRA-UHFFFAOYSA-N catharanthine Natural products C1C(CC)(O)CC(CC2C(=O)OC)CN1CCC1=C2NC2=CC=CC=C12 GKWYINOZGDHWRA-UHFFFAOYSA-N 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000003541 clastogenic effect Effects 0.000 description 2
- 231100000010 clastogenicity Toxicity 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000000039 congener Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 231100000734 genotoxic potential Toxicity 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 210000001753 habenula Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 238000001690 micro-dialysis Methods 0.000 description 2
- 210000000479 mitotic spindle apparatus Anatomy 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 229940126662 negative allosteric modulator Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000003367 nicotinic antagonist Substances 0.000 description 2
- 231100001079 no serious adverse effect Toxicity 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000036390 resting membrane potential Effects 0.000 description 2
- 210000000614 rib Anatomy 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108091005932 CCKBR Proteins 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102100038496 Cysteinyl leukotriene receptor 1 Human genes 0.000 description 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 206010013012 Dilatation ventricular Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000882759 Homo sapiens Cysteinyl leukotriene receptor 1 Proteins 0.000 description 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010022520 Intention tremor Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000016924 KATP Channels Human genes 0.000 description 1
- 108010053914 KATP Channels Proteins 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229940095474 NMDA agonist Drugs 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229940123859 Nicotinic receptor antagonist Drugs 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101100168374 Oryctolagus cuniculus CYP2C1 gene Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004598 abnormal eye movement Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 201000002934 first-degree atrioventricular block Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000013088 frontal headache Diseases 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000056262 human PPIG Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 208000021803 junctional tachycardia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000036723 left ventricular dilatation Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000031868 operant conditioning Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- MQAYFGXOFCEZRW-UHFFFAOYSA-N oxane-2-carboxylic acid Chemical compound OC(=O)C1CCCCO1 MQAYFGXOFCEZRW-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 231100000316 potential neurotoxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 231100001072 toxicokinetic profile Toxicity 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000004515 ventral tegmental area Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Description
WO 2021/067549 PCT/US2020/053726 18-MC FOR TREATMENT OF SUBSTANCE USE DISORDERS BACKGROUND OF THE INVENTION 1. TECHNICAL FIELD 1. 1. 1. id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1" id="p-1"
id="p-1"
[0001] The present invention relates to compositions and methods for treating substance use disorders. 2. BACKGROUND ART 2. 2. 2. id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2" id="p-2"
id="p-2"
[0002] Substance use disorders (SUD) represent a major public health and social issue worldwide. In the United States (US), drug and alcohol misuse and abuse are currently leading causes of death, disability, and disease. In addition, current misuse and abuse of prescription medications (including opioids and benzodiazepines) is epidemic, doubling in the last decade and now responsible for more deaths than motor vehicle accidents (Centers for Disease Control and Prevention [CDC], 2011). The financial cost of SUDs to society, including the cost of treating drug and alcohol abuse, the cost of secondary illnesses and injuries, and lost earnings and years of life due to abusers’ illness, incarcerations, and premature death, is staggering. It has been estimated that the cost of drug and alcohol abuse to US society is nearly a half trillion dollars each year (National Institute on Drug Abuse [NIDA], 2010). 3. 3. 3. id="p-3" id="p-3" id="p-3" id="p-3" id="p-3" id="p-3" id="p-3"
id="p-3"
[0003] Currently, there are limited effective pharmacotherapies for the treatment of SUDs. The only medications approved for SUDs by the US Food and Drug Administration (FDA) are for nicotine and opiate use disorders, and their efficacy is considered to be modest (Marsch, 1998). 4. 4. 4. id="p-4" id="p-4" id="p-4" id="p-4" id="p-4" id="p-4" id="p-4"
id="p-4"
[0004] U.S. Patent Application No. 14/387,339 to Glick, et al. discloses methods of preventing drug relapse, especially during cue inducement, by administering an effective amount of an oi3(34 nicotinic antagonist (18— Methoxycoronaridine) to a mammal, after an initial period of drug use, and preventing a relapse of drug use. It was shown that rats conditioned with a musical cue show increased drug-seeking behaviors with cocaine when compared to control groups. At the time of this application, the mechanism of action of 18-MC was not completely understood, nor was there evidence that it would be effective in humans. . . . id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5" id="p-5"
id="p-5"
[0005] Therefore, a need exists for safe, effective, orally-available, and low-cost pharmacologic approaches to treat SUDs, particularly cocaine disorders for which there are currently no approved therapies.
SUMMARY OF THE INVENTION 6. 6. 6. id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6" id="p-6"
id="p-6"
[0006] The present invention provides for a composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. 7. 7. 7. id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7" id="p-7"
id="p-7"
[0007] The present invention provides for a method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier 1 WO 2021/067549 PCT/US2020/053726 to an individual and preventing substance abuse in the individual. 8. 8. 8. id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8" id="p-8"
id="p-8"
[0008] The present invention provides for a method of preventing addictive behavior in an individual, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing addictive behavior in the individual. 9. 9. 9. id="p-9" id="p-9" id="p-9" id="p-9" id="p-9" id="p-9" id="p-9"
id="p-9"
[0009] The present invention also provides for a method of preventing craving in an individual, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing craving in the individual. . . . id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10" id="p-10"
id="p-10"
[00010] The present invention also provides for the composition of a metabolite of 18-MC salt. 11. 11. 11. id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11" id="p-11"
id="p-11"
[00011] The present invention further provides for a method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual.
DESCRIPTION OF THE DRAWINGS 12. 12. 12. id="p-12" id="p-12" id="p-12" id="p-12" id="p-12" id="p-12" id="p-12"
id="p-12"
[00012] Other advantages of the present invention are readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein: 13. 13. 13. id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13" id="p-13"
id="p-13"
[00013] FIGURE 1 is the chemical structure of 18-Methoxycoronaridine hydrochloride (18-MC HCI); 14. 14. 14. id="p-14" id="p-14" id="p-14" id="p-14" id="p-14" id="p-14" id="p-14"
id="p-14"
[00014] FIGURE 2 is a representative tracing for 18-MC receptor binding; . . . id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15" id="p-15"
id="p-15"
[00015] FIGURE 3 is a graph of 18-MC effect on cocaine self-administration in rats; 16. 16. 16. id="p-16" id="p-16" id="p-16" id="p-16" id="p-16" id="p-16" id="p-16"
id="p-16"
[00016] FIGURE 4 is a graph of acute effects of 18-MC on cocaine self-administration in rats; 17. 17. 17. id="p-17" id="p-17" id="p-17" id="p-17" id="p-17" id="p-17" id="p-17"
id="p-17"
[00017] FIGURE 5 is a dose-response curve for 18-MC effect on cocaine self-administration in rats, measured 1 hour after treatment; 18. 18. 18. id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18" id="p-18"
id="p-18"
[00018] FIGURE 6 is a graph of plasma concentrations of 18-MC following single oral administration in rats; 19. 19. 19. id="p-19" id="p-19" id="p-19" id="p-19" id="p-19" id="p-19" id="p-19"
id="p-19"
[00019] FIGURE 7 is a graph of the relationship between inhibition of cocaine self-administration and plasma concentrations; . . . id="p-20" id="p-20" id="p-20" id="p-20" id="p-20" id="p-20" id="p-20"
id="p-20"
[00020] FIGURE 8 is a graph of the inhibition of cocaine self-administration following repeat dosing with 600 mg/kg/day 18-MC for 5 days in rats; 21. 21. 21. id="p-21" id="p-21" id="p-21" id="p-21" id="p-21" id="p-21" id="p-21"
id="p-21"
[00021] FIGURE 9 is a graph of the relationship between inhibition of cocaine self-administration and 18-MC plasma concentrations in rats following a single dose administration; 22. 22. 22. id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22" id="p-22"
id="p-22"
[00022] FIGURE 10 is a graph of 18-MC effect on sensitized dopamine response in rats; 23. 23. 23. id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23" id="p-23"
id="p-23"
[00023] FIGURE 11 is a graph showing effects of music conditioning on active lever responding during daily cocaine self-administration sessions, extinction, and the reinstatement test session in rats; WO 2021/067549 PCT/US2020/053726 24. 24. 24. id="p-24" id="p-24" id="p-24" id="p-24" id="p-24" id="p-24" id="p-24"
id="p-24"
[00024] FIGURE 12 is a graph of hERG potassium channel inhibition by 18-MC; . . . id="p-25" id="p-25" id="p-25" id="p-25" id="p-25" id="p-25" id="p-25"
id="p-25"
[00025] FIGURE 13 is a graph of the effect of 18-MC on action potential duration in rabbit cardiac Purkinje fibers; 26. 26. 26. id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26" id="p-26"
id="p-26"
[00026] FIGURE 14 is a graph of the change in mean heart rate after oral administration of 18-MC in CD—1 mice; 27. 27. 27. id="p-27" id="p-27" id="p-27" id="p-27" id="p-27" id="p-27" id="p-27"
id="p-27"
[00027] FIGURE 15 is a graph of the change in mean systolic blood pressure after oral administration of 18-MC in CD—1 mice; 28. 28. 28. id="p-28" id="p-28" id="p-28" id="p-28" id="p-28" id="p-28" id="p-28"
id="p-28"
[00028] FIGURE 16 is a graph of the change in mean diastolic blood pressure after oral administration of 18-MC in CD—1 mice; 29. 29. 29. id="p-29" id="p-29" id="p-29" id="p-29" id="p-29" id="p-29" id="p-29"
id="p-29"
[00029] FIGURE 17 is a graph of the average concentrations of 18-MC, M2, M4 and M5 (log- Iinear), cohort B (4 mg at 0 and + 10 hours) in humans; . . . id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30" id="p-30"
id="p-30"
[00030] FIGURE 18A is a concentration response curve for M4, FIGURE 18B is a concentration response curve for M4, FIGURE 18C is concentration response curve for M5, FIGURE 18D is a concentration response curve for M5, and FIGURE 18E is a dose response curve for M4, M5, and 18MC; 31. 31. 31. id="p-31" id="p-31" id="p-31" id="p-31" id="p-31" id="p-31" id="p-31"
id="p-31"
[00031] FIGURES 19A and 19B are graphs showing 18-MC pre-binds in the absence of ACh and continues to accelerate ACh— evoked current decay for some time alter removal; 32. 32. 32. id="p-32" id="p-32" id="p-32" id="p-32" id="p-32" id="p-32" id="p-32"
id="p-32"
[00032] FIGURES 20A-20D are graphs showing M4 and M5 binding profiles; 33. 33. 33. id="p-33" id="p-33" id="p-33" id="p-33" id="p-33" id="p-33" id="p-33"
id="p-33"
[00033] FIGURE 21A is the chemical structure of M4, FIGURE 21B is the chemical structure of M5, FIGURE 21C is the chemical structure of M1, FIGURE 21D is the chemical structure of M2, FIGURE 21E is the chemical structure of M3, FIGURE 21F is the chemical structure of M6 and M7, FIGURE 21G is the chemical structure of M8 and M9, FIGURE 21 H is the chemical structure of M10, FIGURE 21 I is the chemical structure of P1, and FIGURE 21J is the chemical structure of P2 and P3; 34. 34. 34. id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34" id="p-34"
id="p-34"
[00034] FIGURE 22 is a graph of the effects of MC-18 on ICSS in rats; and . . . id="p-35" id="p-35" id="p-35" id="p-35" id="p-35" id="p-35" id="p-35"
id="p-35"
[00035] FIGURE 23A is a graph of MC-18 effects on T0 and FIGURE 23B is a graph of MC-18 effects on M50.
DETAILED DESCRIPTION OF THE INVENTION 36. 36. 36. id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36" id="p-36"
id="p-36"
[00036] The present invention provides for a composition and method for treating substance use disorders. More specifically, the present invention provides for a composition for treating substance use disorders of an effective amount of 18—Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. 37. 37. 37. id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37" id="p-37"
id="p-37"
[00037] "Substance use disorder" as used herein, refers to cocaine abuse, smoking cessation, opiate withdrawal, or any other substance that can be abused. In other words, an individual can be treated for using substances such as cocaine, nicotine, opiates, alcohol, morphine, WO 2021/067549 PCT/US2020/053726 methamphetamine, or other substances. Behavioral disorders can also be treated in the present invention. 38. 38. 38. id="p-38" id="p-38" id="p-38" id="p-38" id="p-38" id="p-38" id="p-38"
id="p-38"
[00038] "Individual" as used herein, refers to mammals, and preferably to humans. While 18-MC has previously been used in rats to prevent cue—induced drug relapse, it was unexpected that it would work in humans. Furthermore, the data shown below regarding human studies was not predictable based on animal studies. 39. 39. 39. id="p-39" id="p-39" id="p-39" id="p-39" id="p-39" id="p-39" id="p-39"
id="p-39"
[00039] 18-MC has demonstrated activity in several animal models of addiction, including those involving nicotine, cocaine, alcohol, morphine, and methamphetamine. 18-MC is effective against many addictive substances because it works in the brain’s pleasure center to prevent craving. 40. 40. 40. id="p-40" id="p-40" id="p-40" id="p-40" id="p-40" id="p-40" id="p-40"
id="p-40"
[00040] The free base 18—methoxycoronaridine (18-MC) is a synthetic coronaridine congener and a specific negative allosteric modulator (antagonist) of oi3B4 nicotinic cholinergic receptors; it indirectly modulates the dopaminergic mesolimbic pathway via blockade of oi3B4 nicotinic receptors in the habenulo—interpeduncular pathway and the basolateral amygdala (Glick et al., 2008). Animal studies have demonstrated that 18-MC significantly reduces drug self-administration in a number of substance use models (nicotine, alcohol, morphine, cocaine and methamphetamine) at dosages as low as 10 mg/kg i.p. (Glick et al., 1994; Rezvani et al., 1995; Glick et al., 1996; Glick et al., 1998; Glick et al., 2000a). More recently, 18-MC has been shown in an animal model to attenuate effects of the environmental cues responsible for stimulating cocaine-seeking or "craving" behaviors (Polston et al., 2012, and US. Patent Application No. 14/387,339 to Glick, et al.). This property of 18-MC could potentially help address the craving component of human addictive behaviors. 41. 41. 41. id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41" id="p-41"
id="p-41"
[00041] The salt is preferably hydrochloride, however other salts can also be used. 18-MC HCI is a soluble salt form of 18-MC, shown in FIGURE 1 (C22H29N203C|, molecular weight 404.97 g/mol). 18-MC HCI is the lead candidate from a library of synthetic coronaridine congeners described by Glick and colleagues (1994). It has a broader potential application in SUDs because its mechanism of action is central to addiction behavior per se, rather than to specific chemical substances of abuse. 18-MC HCI is a specific negative allosteric modulator or (antagonist) of 0:364 nicotinic cholinergic receptors that indirectly modulates the dopaminergic mesolimbic pathway by blocking oi3[34 nicotinic receptors in the habenulo—interpeduncular pathway and the basolateral amygdala (Glick et al, 2008).
Animal studies have demonstrated that a single dose of 18-MC HCI as low as 10 mg/kg i.p. can significantly reduce drug self-administration in a number of substance use models (nicotine, alcohol, morphine, cocaine and methamphetamine) (Glick et al, 1994; Rezvani et al, 1995; Glick et al, 1996; Glick et al, 1998; Glick et al, 2000a). More recently, 18-MC HCI has been shown in an animal model to attenuate the effects of environmental cues responsible for stimulating cocaine-seeking or "craving" behaviors (Polston et al, 2012). This property of 18-MC could potentially help address another WO 2021/067549 PCT/US2020/053726 important component of human addictive behaviors — namely, craving. 42. 42. 42. id="p-42" id="p-42" id="p-42" id="p-42" id="p-42" id="p-42" id="p-42"
id="p-42"
[00042] 18-MC reduces the reinforcing effects of addictive drugs and decreases self- administration of cocaine and other addictive drugs in rats. Mechanistic studies have shown that 18- MC acts as an allosteric, noncompetitive antagonist of the nicotinic acetylcholine (nACh) q3B4 receptor. The 0864 nACh receptor is predominantly localized in two brain nuclei: the medial habenula and the interpeduncular nucleus. 18-MC has at least 20-fold higher affinity for or3B4 than for oi4B2 nACh receptors (which are expressed ubiquitously in the brain), or for NMDA or 5HT3 receptors (Glick et al, 2002). Local administration of 18-MC into the interpeduncular nuclei or medial habenula can reduce drug self-administration (e.g., of methamphetamine), whereas local administration of 18-MC into the ventral tegmental area has no such effect. Consistent with these behavioral findings, systemic administration of 18-MC attenuates the sensitizing effects of repeated cocaine treatments on dopamine release in the nucleus accumbens. Lastly, in a well-characterized animal model for "craving" behaviors, 18-MC attenuated the effects of the environmental cues responsible for stimulating cocaine-seeking behavior. 43. 43. 43. id="p-43" id="p-43" id="p-43" id="p-43" id="p-43" id="p-43" id="p-43"
id="p-43"
[00043] Formulation and mg 44. 44. 44. id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44" id="p-44"
id="p-44"
[00044] 18-MC HCI can be supplied as a dry powder packaged in double plastic bags in an HDPE bottle with desiccant. The 18-MC HCI can be formulated at the clinical site into a solution for closing patients. 18-MC HCI is soluble in water (pH 2.5) up to 30 g/ml. 18-MC HCI is poorly soluble in aqueous solution at neutral and alkaline pH. 18-MC HCI is freely soluble in dimethyl sulfoxide (DMSO). Based on the properties of the compound, it can also be formulated in a solid oral formulation (tablet, capsule, sachets, granules, etc.) 45. 45. 45. id="p-45" id="p-45" id="p-45" id="p-45" id="p-45" id="p-45" id="p-45"
id="p-45"
[00045] Most preferably, an oral dose of the composition is used. An oral dosing formulation was validated by a GLP study. The maximum solubility of 18-MC HCI is 40 mg/mL in 5% dextrose (pH 3.0). 18-MC HCI properties (homogeneity and concentration acceptability, solubility, and stability after days of refrigerated storage) met the applicable ICH criteria. The 18-MC HCI dosing solution also met the required stability criteria after 3 freeze-thaw (20°C) cycles. 46. 46. 46. id="p-46" id="p-46" id="p-46" id="p-46" id="p-46" id="p-46" id="p-46"
id="p-46"
[00046] 18-MC HCI is synthesized in five steps, starting with two proprietary, non-GMP starting materials (an aldehyde and an indole) and completed as the HCI salt of 18-MC. The 18-MC HCI is a racemate with a 1:1 ratio of the two enantiomers. 47. 47. 47. id="p-47" id="p-47" id="p-47" id="p-47" id="p-47" id="p-47" id="p-47"
id="p-47"
[00047] 18-MC can be administered in a dose from 0.01—10 mg/kg. Animal studies described below showed that the no-observed-effect level (NOEL) and no-observed-adverse-effect level (NOAEL) were 90 mg/kg and 400 mg/kg. Clinical studies in Example 6 showed that a 20 mg dose once a day is safe in humans. A more preferable dose can be 4 mg twice a day in humans. 48. 48. 48. id="p-48" id="p-48" id="p-48" id="p-48" id="p-48" id="p-48" id="p-48"
id="p-48"
[00048] The compound of the present invention is administered and dosed in accordance with WO 2021/067549 PCT/US2020/053726 good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art. 49. 49. 49. id="p-49" id="p-49" id="p-49" id="p-49" id="p-49" id="p-49" id="p-49"
id="p-49"
[00049] In the method of the present invention, the compound of the present invention can be administered in various ways. It should be noted that it can be administered as the compound and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles. The compounds can be administered orally, subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally, intratonsillar, and intranasal administration as well as intrathecal and infusion techniques. Implants of the compounds are also useful. The patient being treated is a warm-blooded animal and, in particular, mammals including man. The pharmaceutically acceptable carriers, diluents, adjuvants and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention. 50. 50. 50. id="p-50" id="p-50" id="p-50" id="p-50" id="p-50" id="p-50" id="p-50"
id="p-50"
[00050] The doses can be single doses or multiple doses over a period of several days. The treatment generally has a length proportional to the length of the disease process and drug effectiveness and the patient species being treated. 51. 51. 51. id="p-51" id="p-51" id="p-51" id="p-51" id="p-51" id="p-51" id="p-51"
id="p-51"
[00051] When administering the compound of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion). The pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions. The carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. 52. 52. 52. id="p-52" id="p-52" id="p-52" id="p-52" id="p-52" id="p-52" id="p-52"
id="p-52"
[00052] Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
Nonaqueous vehicles such a cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, may also be used as solvent systems for compound compositions. Additionally, various additives which enhance the stability, sterility, and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and WO 2021/067549 PCT/US2020/053726 the like. In many cases, it will be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds. 53. 53. 53. id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53" id="p-53"
id="p-53"
[00053] Sterile injectable solutions can be prepared by incorporating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired. 54. 54. 54. id="p-54" id="p-54" id="p-54" id="p-54" id="p-54" id="p-54" id="p-54"
id="p-54"
[00054] A pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres. Examples of delivery systems useful in the present invention include: ,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196. Many other such implants, delivery systems, and modules are well known to those skilled in the art. 55. 55. 55. id="p-55" id="p-55" id="p-55" id="p-55" id="p-55" id="p-55" id="p-55"
id="p-55"
[00055] Pharmacokinetics 56. 56. 56. id="p-56" id="p-56" id="p-56" id="p-56" id="p-56" id="p-56" id="p-56"
id="p-56"
[00056] In all the species tested in pre-clinical studies, 18-MC is rapidly absorbed following oral administration with Tmax occurring in less than 0.5 hours following oral administration. After oral administration, the elimination of 18-MC is multi-compartmental. In plasma, 18-MC is highly protein bound (92% to 98%). 18-MC is also rapidly and extensively metabolized, presumably by first pass metabolism. At least 13 different metabolites have been detected both in vitro and in vivo, further described below (M1-M9, P1-P3). The major metabolites (those with exposure greater than 10% of the total drug related material) appear to change with the dose and duration of dosing. Major metabolites include M2, M4, M5, M8, M9 and P2 depending on the animal species tested, and the dose and duration of dosing. 57. 57. 57. id="p-57" id="p-57" id="p-57" id="p-57" id="p-57" id="p-57" id="p-57"
id="p-57"
[00057] When administered orally, 18-MC is a very minor percentage of the circulating drug material (<1% in the mouse after a dose of 25 mg/kg/day and <3% in the monkey after a dose of 300 mg/kg/day). 58. 58. 58. id="p-58" id="p-58" id="p-58" id="p-58" id="p-58" id="p-58" id="p-58"
id="p-58"
[00058] In a GLP oral toxicology study in mice, after 14 days of administration of 25 mg/kg 18-MC HCI, the major metabolites were M2>M4>>M9>M8, with 18-MC being <1% of all drug-related material. The exposure to 18-MC were Cmax 105 ng/mL and AUC 251 ngxhr/mL. The elimination half- life following an oral dose of 25 mg/kg 18-MC HCI was 3 to 4 hours in both sexes and about 2 hours WO 2021/067549 PCT/US2020/053726 for the major metabolites. 59. 59. 59. id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59" id="p-59"
id="p-59"
[00059] In a GLP oral toxicology study in monkeys, after 14 days of administration of 300 mg/kg 18-MC HCI, the relative frequency of metabolites was M5>>M2>P2, with 18-MC less than 3% of the total circulating drug—related material. On Day 14, the exposure to 18-MC was Cmax 144 ng/mL and AUC 1210 ngxhr/mL. 60. 60. 60. id="p-60" id="p-60" id="p-60" id="p-60" id="p-60" id="p-60" id="p-60"
id="p-60"
[00060] The enzymes that metabolize 18-MC have not yet been identified, but 18-MC has been shown to moderately inhibit CYP2C9 and CYP2C19 and, to a lesser extent, CYP2C8, CYP2E1 and CYP3A4. 61. 61. 61. id="p-61" id="p-61" id="p-61" id="p-61" id="p-61" id="p-61" id="p-61"
id="p-61"
[00061] Pharmacology 62. 62. 62. id="p-62" id="p-62" id="p-62" id="p-62" id="p-62" id="p-62" id="p-62"
id="p-62"
[00062] The pharmacological activity of 18-MC and two of the major metabolites were tested by whole-cell patch clamp recording of HEK 293 cells expressing recombinant ol3B4 nACh receptors (Pace et al (2004)). Application of 1 mM acetylcholine (Ach) produced a large, inward, desensitizing current similar. 18-MC inhibited the Ach-evoked currents with an |C5o value of 0.8 uM. 63. 63. 63. id="p-63" id="p-63" id="p-63" id="p-63" id="p-63" id="p-63" id="p-63"
id="p-63"
[00063] The binding potential of 18-MC with 64 neurotransmitter-related binding sites was evaluated. At 10 uM 18-MC, binding was seen to the adrenergic a|pha—1 receptor, Mu opioid receptor, and sodium site 2 channel ligands; this concentration of 18-MC, however, is several orders of magnitude greater than the expected human plasma concentration of unbound 18-MC. 64. 64. 64. id="p-64" id="p-64" id="p-64" id="p-64" id="p-64" id="p-64" id="p-64"
id="p-64"
[00064] In a CNS safety pharmacology study, as would be expected given the known pharmacological activity of 18-MC and its effects upon central dopaminergic activity, the administration of 18-MC in rats was characterized by depressed motor function and increased sedation. Other effects included slower respiration rate, decreased cutaneous blood flow, increased pupil diameter and decreased body temperature. All of these findings were transient and dose dependent with increased frequency and occurrence corresponding to increased dose. The time of peak effect occurred between 90 and 150 minutes post-dosing and subsided at 6 hours post-dose. 65. 65. 65. id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65" id="p-65"
id="p-65"
[00065] In vitro, 18-MC inhibited hERG ionic conductance and reduced action potential duration in rabbit purkinje fibers. However, single oral administration of 18-MC HCI at doses of 30, 90, or 270 mg/kg to male radio telemetry-implanted cynomolgus monkeys did not affect cardiovascular parameters, body temperature, or respiratory parameters. Apart from emesis at the highest dose, 18- MC HCI was generally well tolerated in monkeys. The no—observed—effect level (NOEL) on both the cardiovascular and the respiratory systems was determined to be 270 mg/kg. There was also no evidence of any electrocardiographic abnormalities in monkeys treated with 18-MC HCI for 2 weeks up to an oral dose of 300 mg/kg/day in the 2-week toxicology study. The basis for a potential discrepancy between the in vitro and in vivo findings is not known but could be related to differences in the disposition of 18-MC such as metabolism and protein binding, since 18-MC is both highly WO 2021/067549 PCT/US2020/053726 metabolized and highly protein bound in vivo. In both mice and monkeys, for instance, 18-MC is significantly metabolized with parent drug representing only a fraction of the exposure represented by metabolites. 66. 66. 66. id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66" id="p-66"
id="p-66"
[00066] 18-MC has been studied for its effects on the hERG channel and the rabbit Purkinje fibers action potential duration (ADP). 18-MC prolonged the hERG and decreased the ADP. The significance of these observations is not known because 18-MC is only a minor component of the circulating 18-MC drug related material, and information on the metabolites have not been studied in these in vitro systems. In instrumented monkeys, the administration of 18-MC had no effect on electrocardiographic intervals or cardiovascular function. The collective in vitro and in vivo data suggest that 18-MC does not pose a significant pro—arrhythmic liability. Given the low proposed starting dose and cautious dose escalation scheme, the risk for untoward cardiovascular events in a clinical trial is considered low. 67. 67. 67. id="p-67" id="p-67" id="p-67" id="p-67" id="p-67" id="p-67" id="p-67"
id="p-67"
[00067] During the close finding studies in animals, acute death was observed at some doses within 1.5 to 4 hours after 18-MC HCI administration, with mice being the most sensitive. However, the cause of death could not be identified upon necropsy. The acute effects of oral administration in mice of 100 mg/kg followed 8 hours later by a second dose of 200 mg/kg of 18-MC HCI on arterial blood pressure, heart rate, and body temperature were further investigated in radio-telemetered mice.
After the initial dose, behavioral effects prior to death included tremors, twitches, abnormal gait, lethargy, decreased motor activity, increased response to touch and startle, seizures, gasping and slow respirations, exophthalmia and stupor. The peak effects occurred between 90 and 150 minutes after the oral administration of 18-MC HCI. Following the second dose, all animals exhibited similar reactions to the upper dose of 200 mg/kg and were within one hour of dosing as follows: average heart rate decreased about 50%, and significant decreases in systolic and diastolic blood pressure, and internal body temperature were seen. Terminally, there was a further decrease in all of the parameters being measured, with the temperature falling steeply (to as low as 22 °C in one mouse) before the mice died. 68. 68. 68. id="p-68" id="p-68" id="p-68" id="p-68" id="p-68" id="p-68" id="p-68"
id="p-68"
[00068] Based on the safety pharmacology, clinical pathological and vital signs (including heart rate, blood pressure, and body temperature) can be closely monitored as changes in neurobehavior, clinical pathology, vital signs or body temperature are expected to serve as useful premonitory markers by which to limit dosing and protect subjects against the occurrence of significant adverse effects. 69. 69. 69. id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69" id="p-69"
id="p-69"
[00069] Toxicology 70. 70. 70. id="p-70" id="p-70" id="p-70" id="p-70" id="p-70" id="p-70" id="p-70"
id="p-70"
[00070] The results of single—dose studies in rodents, dogs, and monkeys indicated as expected, the known pharmacological profile of 18-MC, that the oral administration of 18-MC HCI produced WO 2021/067549 PCT/US2020/053726 transient, dose-related neurobehavioral changes. Single doses up to 300-400 mg/kg and 800 mg/kg appeared to be generally well tolerated in monkeys and rats, respectively (one monkey treated with 400 mg/kg died in the 2-week GLP study on Day 1 of dosing). Emesis in dogs was seen at a lower dose (100 mg/kg), limiting the utility of this model for characterizing the toxicology profile of 18-MC HCI. In mice, mortality was consistently seen following single closes 2150 mg/kg. Preliminary 5-day repeat—dose range—finding studies were conducted in mice, rats and monkeys. The definitive 14-day studies in mouse and monkey yielded generally similar results to those observed in the 5-day studies. 71. 71. 71. id="p-71" id="p-71" id="p-71" id="p-71" id="p-71" id="p-71" id="p-71"
id="p-71"
[00071] In a 2-week GLP study in mice (the most sensitive species), doses of 0 (vehicle), 25, 50, or 100 mg/kg/day were administered for 14 days by oral gavage following a 2 to 4 day dose-up titration. In the GLP study, two male mice in the 100 mg/kg/day group were found dead on Days -1 and 12. The cause of death in the two animals was undetermined though anatomical pathology findings consisted of atrial and/or ventricular dilatation. In the animal that died on Day -1, this animal had received 3 doses of 18-MC HCI (25, 50 and 75 mg/kg) as part of an up-titration to the top dose of 100 mg/kg. There were no clinical findings which preceded the death of this animal. The other animal that died on Day 12 also exhibited similar anatomical pathology changes in the heart as well as several neurobehavioral observations (including clonic convulsions) prior to death clearly indicating that the death was test article-related. Clinical pathology effects in surviving animals were limited to dose-related reductions in total white blood cell counts and lymphocytes and a slight increase in serum cholesterol (100 mg/kg/day males). The no-observed-adverse-effect-level (NOAEL) in this study was 50 mg/kg/day in males (based upon the death of two high-dose males) and 100 mg/kg/day in females. There were no histopathology findings (including no neuropathology findings) in the dead mice that were attributable to 18-MC HCI. 72. 72. 72. id="p-72" id="p-72" id="p-72" id="p-72" id="p-72" id="p-72" id="p-72"
id="p-72"
[00072] In a 2-week GLP study in monkeys, neurobehavioral signs consistent with the expected pharmacological activity of 18-MC HCI were noted in high-dose animals (5 males/5 females) and one male died following the administration of 400 mg/kg on the first day of dosing (the dose level was reduced from 400 mg/kg to 300 mg/kg from Day 2 onward). There were no other deaths in this study.
Treatment with 18-MC HCI was associated with a slight reduction in body weight/body weight gain (doses 250 mg/kg/day), hematological effects, and bone marrow changes in 150 mg/kg/day males and 400/300 mg/kg/day animals. The predominant serum chemistry change noted was a reduction in alkaline phosphatase relative to controls across all dose levels; this decrease was not judged to be of toxicologic importance. Mildly reduced weight in the thymus was observed at 50 mg/kg/day and at 400/300 mg/kg/day, which correlated microscopically with test article-related generalized lymphoid depletion. No neuropathological alterations attributable to 18-MC HCI were observed. Based upon the results of this study, the NOAEL in this study was 50 mg/kg/day.
WO 2021/067549 PCT/US2020/053726 73. 73. 73. id="p-73" id="p-73" id="p-73" id="p-73" id="p-73" id="p-73" id="p-73"
id="p-73"
[00073] In the genetic toxicology studies, although 18-MC HCI was found to be positive in the in vitro chromosome aberration assay in the presence (but not absence) of metabolic activation, no evidence of genotoxicity was seen in the in vitro Ames assay or in the two in vivo studies conducted (mouse micronucleus and comet assays). The collective results indicate that 18-MC does not pose a significant genotoxic risk. 74. 74. 74. id="p-74" id="p-74" id="p-74" id="p-74" id="p-74" id="p-74" id="p-74"
id="p-74"
[00074] Clinical Study 75. 75. 75. id="p-75" id="p-75" id="p-75" id="p-75" id="p-75" id="p-75" id="p-75"
id="p-75"
[00075] An FTIH study of 18-MC HCI described in Example 6 is a Phase 1, randomized, double- blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of 18-MC. 76. 76. 76. id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76" id="p-76"
id="p-76"
[00076] The primary objective of the study is to assess the safety and tolerability of 18-MC HCI following oral administration of single ascending doses given to healthy male and female (of non- childbearing potential) volunteers. 77. 77. 77. id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77" id="p-77"
id="p-77"
[00077] The secondary objectives are 1) to characterize the PK of 18-MC in plasma following oral administration of single ascending doses, 2) to detect and quantify metabolites (if a validated assay is available or report the relative metabolite ratios) of 18-MC in plasma, 3) to characterize the PD effects and duration of PD effects of 18-MC following oral administration of single ascending doses, 4) as an experimental objective, the relative concentration of 18-MC and metabolites in the urine may be determined. 78. 78. 78. id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78" id="p-78"
id="p-78"
[00078] Based upon the nonclinical toxicology studies conducted to date, the predominant adverse findings in mice and monkeys were exaggerated acute neurobehavioral findings consistent with the known pharmacological activity of 18-MC. In the pivotal 2-week studies, 18-MC HCI was well tolerated in mice at doses up to 100 mg/kg/day in female mice and 50 mg/kg/day in male mice, which correspond to HEDs of 8 and 4 mg/kg/day, respectively. These doses also correspond to the highest non—lethal doses in this species. In monkeys, 18-MC HCI was well tolerated at a dose of 50 mg/kg/day (corresponding to an HED of 16 mg/kg/day). The highest non—lethal dose for monkeys was 300 mg/kg. 79. 79. 79. id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79" id="p-79"
id="p-79"
[00079] In the FTIH study, the initial clinical dose was proposed to be 20 mg which is based on the non—lethal dose in the most sensitive species, mouse, and which was determined as follows. The non—lethal dose in mice is 50 mg/kg which has a HED of 4 mg/kg. This value is multiplied by 1/10"‘ for an additional safety correction factor resulting in an HED of 0.4 mg/kg (which corresponds to a human dose of 28 mg). To be conservative then, the starting dose can be 20 mg instead of 28 mg for an additional safety factor. The study showed that high plasma levels occurred at 20 mg, and so a lower dose of 4 mg twice daily was examined. No serious adverse events were reported. 80. 80. 80. id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80" id="p-80"
id="p-80"
[00080] For dose escalation in the FTIH study, drug exposure limits can be set by 1/1 0th of the 11 WO 2021/067549 PCT/US2020/053726 exposure in the mouse, and safety stopping criteria are detailed in the protocol. 81. 81. 81. id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81" id="p-81"
id="p-81"
[00081] The studies showed that the pharmacokinetics appeared to follow a multiple-compartment model and the elimination half-life of 18-MC and the metabolites was about 48 hours. 18-MC has a short distribution half-life and longer terminal half-life. 82. 82. 82. id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82" id="p-82"
id="p-82"
[00082] The results from the nonclinical safety pharmacology and toxicology studies predict that 18-MC can affect the central and/or autonomic nervous, cardiovascular, immune and hematopoietic systems at doses significantly higher than are proposed. The protocol incorporates appropriate precautionary measures and a cautious dose-escalation scheme to limit the chance for significant adverse events. Based upon the results of safety pharmacology and mouse toxicology studies, vital signs (including body temperature) can be closely monitored as part of the proposed clinical trial. 83. 83. 83. id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83" id="p-83"
id="p-83"
[00083] The present invention provides for a method of treating substance use disorders, by administering an effective amount of 18-MC HCI in a pharmaceutical carrier to an individual and preventing substance abuse. Preferably, the 18-MC HCI is in an oral dosage form. The substance can be any of those described above. Administration can be at any of the dosing ranges described above, and more preferably 20 mg or less per day. 18-MC HCI is highly protein bound and undergoes multi-compartmental elimination. The method further includes the step of 18-MC HCI blocking oi3B4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala. The 18-MC HCI can further inhibit enzymes CYP2C9, CYP2C19, CYP2C8, CYP2E1, and CYP3A4 as described below in Example 4. Example 1 shows that 18-MC HCI can decrease cocaine self-administration dose dependently and has greater effects at higher plasma concentrations. 18- MC HCI can reverse the sensitized dopaminergic response to drugs and decrease the rewarding effect of drugs. 84. 84. 84. id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84" id="p-84"
id="p-84"
[00084] The present invention provides for a method of preventing addictive behavior in an individual, by administering an effective amount of 18-MC HCI in a pharmaceutical carrier to an individual and preventing addictive behavior in the individual. Preferably, the 18-MC HCI is in an oral dosage form. The substance can be any of those described above. Administration can be at any of the dosing ranges described above, and more preferably 20 mg or less per day. The method further includes the step of 18-MC blocking G3|34 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala. The 18-MC can further inhibit enzymes CYP2C9, CYP2C19, CYP2C8, CYP2E1, and CYP3A4. 85. 85. 85. id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85" id="p-85"
id="p-85"
[00085] The present invention also provides for a method of preventing craving in an individual, by administering an effective amount of 18-MC HCI in a pharmaceutical carrier to an individual and preventing craving in the individual. Preferably, the 18-MC HCI is in an oral dosage form. The substance can be any of those described above. Administration can be at any of the dosing ranges 12 WO 2021/067549 PCT/US2020/053726 described above, and more preferably 20 mg or less per day. 18-MC is highly protein bound and undergoes multi-compartmental elimination. The method further includes the step of 18-MC blocking oi3[34 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala. The 18-MC can further inhibit enzymes CYP2C9, CYP2C19, CYP2C8, CYP2E1, and CYP3A4. 86. 86. 86. id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86" id="p-86"
id="p-86"
[00086] The present invention also provides for the composition of a metabolite of 18-MC salt and a method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse. Example 7 shows that metabolites M4 and M5 can bind to the oi3B4 receptors, although with faster dissociation rates than 18-MC, and M5 has a slower association rate. M4 can pre-bind to inhibit nAChRs in the absence or presence of agonist. Metabolites M4 and M5 retain some of the activity of 18-MC, though with reduced potency. 87. 87. 87. id="p-87" id="p-87" id="p-87" id="p-87" id="p-87" id="p-87" id="p-87"
id="p-87"
[00087] The present invention further provides for a composition having the binding profile shown in Figure 2, a composition having an action potential duration in rabbit cardiac Purkinje fibers shown in Figure 13, a composition having a pharmacokinetic profiles of parent and a metabolite in human plasma shown in Figure 17, a composition having an |C5o profiles of parent and one or more metabolites as shown in Figure 18E, a composition having an alpha3-beta4 nicotinic cholinergic receptor patch clamp assay profile as shown in Figures 19A and 19B, a composition having a human metabolite alpha3-beta4 nicotinic cholinergic receptor patch clamp assay profile as shown in any of Figures 20A, 20B, 20C and 20D, and a composition having an ICSS study profile in rats as shown in any of Figures 22, 23, or 24. 88. 88. 88. id="p-88" id="p-88" id="p-88" id="p-88" id="p-88" id="p-88" id="p-88"
id="p-88"
[00088] The invention is further described in detail by reference to the following experimental examples. These examples are provided for the purpose of illustration only and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein. 89. 89. 89. id="p-89" id="p-89" id="p-89" id="p-89" id="p-89" id="p-89" id="p-89"
id="p-89"
[00089] EXAMPLE 1 90. 90. 90. id="p-90" id="p-90" id="p-90" id="p-90" id="p-90" id="p-90" id="p-90"
id="p-90"
[00090] Nonclinical Pharmacology 91. 91. 91. id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91" id="p-91"
id="p-91"
[00091] The pharmacological activity of 18-MC was tested by whole—cell patch clamp recording of HEK 293 cells expressing recombinant oi3[34 nACh receptors, using methods previously described by Pace et al (2004). Application of 1 mM ACh produced a large, inward, desensitizing current with an |C5o Of 18-MC, 0.8 MM. 92. 92. 92. id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92" id="p-92"
id="p-92"
[00092] In vitro and in vivo experiments were conducted to gain understanding about the functional activity of 18-MC. The mechanism of action was examined in electrophysiology studies and the in vivo activity of 18-MC HCI was assessed using a rat model of cocaine self-administration. 13 WO 2021/067549 PCT/US2020/053726 Below is a description of the studies performed. 93. 93. 93. id="p-93" id="p-93" id="p-93" id="p-93" id="p-93" id="p-93" id="p-93"
id="p-93"
[00093] A representative tracing for 18-MC receptor binding is shown in FIGURE 2. Application of 1 mM ACh produced a large, inward, desensitizing current similar to that described previously. The results were consistent with previous studies (Glick et al, 1996; Pace et al, 2004) showing that 18-MC potently inhibited ci3B4 nACh receptors. 94. 94. 94. id="p-94" id="p-94" id="p-94" id="p-94" id="p-94" id="p-94" id="p-94"
id="p-94"
[00094] Intraperitoneal Administration of 18-MC HCI Inhibits Rat Cocaine Self-Administration 95. 95. 95. id="p-95" id="p-95" id="p-95" id="p-95" id="p-95" id="p-95" id="p-95"
id="p-95"
[00095] 18-MC HCI was assessed in a rat cocaine addiction model (Glick et al, 1996). 18-MC dose-dependently decreased cocaine self-administration in rats (FIGURE 3). Note that these effects were selective, in that the same doses of 18-MC HCI did not affect responding for water, a non-drug reinforcer. Female Sprague—Dawley rats weighing approximately 250g were trained to self—administer cocaine hydrochloride (0.4 mg/kg per infusion) or water (0.01 ml per bar-press) during daily one hour test sessions based on a fixed ratio schedule of FR=3. 18-MC HCI (10-40 mg/kg, i.p.) administered minutes prior to the session significantly decreased responding for cocaine but had no effect on responding for water. Each data point is the mean (:S.E.M) from 4-8 rats. All tested doses of 18-MC HCI had significant effects (ANOVA and t—tests, *= p<0.05—0.001). 96. 96. 96. id="p-96" id="p-96" id="p-96" id="p-96" id="p-96" id="p-96" id="p-96"
id="p-96"
[00096] Relationship of Inhibition of Rat Cocaine Self-Administration and 18-MC Plasma Concentrations 97. 97. 97. id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97" id="p-97"
id="p-97"
[00097] The relationship between in vivo efficacy and plasma drug exposure was investigated in rats trained to self—administer cocaine. Trained animals given a single oral dose of 18-MC HCI were placed one hour later into the operant chamber for another hour to record the volume of self- administered cocaine. Blood samples were collected immediately after the one hour session in the operant chamber from the arterial catheter. Repeat measurements for cocaine self-administration were collected at 25, 49, 73, 97, 121, 146 hours following the single oral dose of 18-MC HCI. The inhibitory effects of different 18-MC HCI doses measured over a 7 day period are shown in FIGURE 4. Following stable acquisition of cocaine self-administration (0.32 mg/kg/infusion), 18-MC HCI (or vehicle) was administered p.o. and responding for cocaine was measured at 1 hour (0 days), and subsequently, for 6 days post-treatment. Significant differences from vehicle-treated animals were either p < 0.01 (indicated as **) or p < 0.05 (indicated as *). 98. 98. 98. id="p-98" id="p-98" id="p-98" id="p-98" id="p-98" id="p-98" id="p-98"
id="p-98"
[00098] Cocaine self-administration 1 hour post dose was inhibited by 18-MC HCI in a dose- dependent manner. The inhibitory effect of 18-MC HCI was, however, highly variable among animals.
The inhibitory activity gradually reversed over time and cocaine self-administration was fully restored to baseline values by Day 6 (146 hours post-dose). Inhibition of cocaine self-administration measured at 1 hour post—dose occurred in a dose—dependent manner; cocaine self-administration was inhibited by 50% after the administration of 120 mg/kg and by 82% after dosing with 800 mg/kg dose (FIGURE 14 WO 2021/067549 PCT/US2020/053726 ). Significant difference from vehicle-treated group (0 mg/kg on X axis) was p < 0.01 (indicated as **) by one-way ANOVA. 99. 99. 99. id="p-99" id="p-99" id="p-99" id="p-99" id="p-99" id="p-99" id="p-99"
id="p-99"
[00099] The plasma concentration of 18-MC was highly variable among individual animals (FIGURE 6). The inhibition of cocaine self-administration by 18-MC (at 1 hour post dose) was related to its plasma concentration (at approximately 2 hours post dose) (FIGURE 7). Each data point In FIGURE 7 represents a single animal with its self-administration data were collected at 1 hour post- dose for an hour and its 18-MC plasma concentration in blood samples collected immediately after the recording session at approximately 2 hours post-dose. Dotted lines are the upper and lower bounds of the 95% confidence interval (-0.8187 to -0.1395). The data conformed to a second-order fit with R2 = 0.324, p = 0.0137. This observation suggests that plasma drug concentration can be a surrogate predictive of the central effect of 18-MC, as greater efficacy was seen at higher plasma concentrations than at lower concentrations. [0OO100] Repeated dosing with 18-MC HCI (600 mg/kg/day) over 5 consecutive days 1 hour prior to the self-administration session did not result in greater inhibition of cocaine self-administration (FIGURE 8). Significant difference from baseline responding was p < 0.01 (as indicated by **).
Instead, the inhibitory effects on the second to fifth day of dosing were less than the inhibitory effect seen with the first dose. On average, the plasma concentration of 18-MC at 2 hours post-dose was lower on the last day of dosing compared to the first day (TABLE 1). Blood samples were collected from animals immediately after their cocaine self-administration at approximately 2 hours post dose in the first day of dosing (Day 0), and the last day of dosing (Day 4). Pre-dose samples were collected about 1 hour prior to the last dose of 18-MC HCI (on Day 4).
TABLE 1 Plasma 18-MC concentration in individual animals on first and last day of dosing in a 5-day study Dose PK Animal l.D. Plasma 18-MC Day Sampling Concentration (ng/mL) T'"‘° 89224 89225 89228 89232 89237 89243 Average SEM 0 POST dose 3,450 12,600 11,300 13,900 14,200 13,200 11,442 1653_0 4 Pre close 3,340 1,680 3,020 — 2,720 3,730 2,993 391 _1 4 Post dose 9,030 3,760 8,040 — 10,500 6,290 7524 11535 [00O101] All of the available PK data points collected on the first 3 days following dosing were analyzed with their corresponding self-administration values for individual animals. The analysis showed a second-order fit between inhibition of cocaine self-administration and 18-MC plasma concentration with R2 = 0.425 and p<0.0001 (FIGURE 9). Animals were administered a single oral dose of 18-MC HCI and the volumes of self-administered cocaine were recorded at 1, 25, 49, 73, 97, 121, 146 hours post dose. A blood sample was collected after each recording session. All data point WO 2021/067549 PCT/US2020/053726 represents the cocaine self—administration volume and 18-MC plasma concentration in blood samples collected immediately after that particular recording session. Data points with missing 18-MC plasma concentrations were excluded from the analysis. Dotted lines are the upper and lower bounds of the 95% confidence interval (-0.7742 to -0.4845). [00O102] 18-MC Blocks sensitized Dopamine Response to Cocaine in Rat Nucleus Accumbens [0O0103] Because dopamine release in the nucleus accumbens (NAC) has been implicated in the reinforcing actions of drugs of abuse, the effects of systemic 18-MC HCI (40 mg/kg) pretreatment (19 hours beforehand) on the acute and sensitized dopamine responses in the nucleus accumbens shell to cocaine administration were examined (Szumlinski et al, 2000). 18-MC HCI pretreatment had little effect on the acute response to cocaine but abolished the sensitized dopamine response to cocaine. 104. 104. 104. id="p-104" id="p-104" id="p-104" id="p-104" id="p-104" id="p-104" id="p-104"
id="p-104"
[000104] The results indicate that 18-MC HCI can reverse the sensitized dopaminergic response to drugs, which is believed to be the neurochemical substrate of drug craving (FIGURE 10). These results are consistent with evidence that 18-MC decreases the rewarding effects of drugs. Rats were implanted with a microdialysis guide cannula over the shell of the NAC. Rats received daily injections of cocaine (15 mg/kg, i.p.) or saline for 5 days. Following 2 weeks of withdrawal, rats were pretreated with either 18-MC HCI (40 mg/kg, i.p.) or vehicle. The next day a microdialysis experiment was performed and the effects of cocaine (20 mg/kg, i.p.) were assessed. The samples were analyzed by HPLC-EC. N=5-7/group. (Vehicle vs. 18-MC pretreated groups, * = p<0.05) [00O105] 18-MC HCI Blocks Context-Induced Reinstatement of Cocaine Seeking (a "Cravings" Mojtiitell [0O0106] Diminishing drug craving is considered to be a critical component of any treatment of addiction. Several models of craving have been proposed to measure the tendency of rats to respond to stimuli associated with the self—administration of a drug. Polston et al (2012) used prolonged music cues to alter the context of drug self—administration (FIGURE 11). Animals were trained to self- administer cocaine in the presence of music. self—administration behavior was then extinguished over several days in the absence of music. Subsequently, under extinction conditions, when music was re- introduced, it reinstated cocaine seeking behavior (i.e., responding on the cocaine-paired lever). 18- MC HCI (40 mg/kg, i.p.) blocked the reinstatement effect of cues associated with cocaine self- administration. 107. 107. 107. id="p-107" id="p-107" id="p-107" id="p-107" id="p-107" id="p-107" id="p-107"
id="p-107"
[000107] Data depicted as mean cocaine infusions (:SEM) during self—administration trials, and theoretical infusions earned during extinction sessions. Active lever presses (iSEM) during the reinstatement test session are plotted accordingly with the right x-axis. Animals were on an FR1 schedule of reinforcement on days 1-12 and changed to an FR3 schedule for the remainder of the experiment. Animals in the Music condition made significantly more responses on the drug-paired 16 WO 2021/067549 PCT/US2020/053726 lever on the reinstatement test day (Test) than animals in the NMCond and NMTest groups.
Additionally, significant differences were observed on the first day of extinction (Ext 1); animals that had not been conditioned with music during self-administration (NMCond) made significantly more responses than animals that had been trained with music. * p<0.05, *** p<.001. 108. 108. 108. id="p-108" id="p-108" id="p-108" id="p-108" id="p-108" id="p-108" id="p-108"
id="p-108"
[000108] EXAMPLE 2 109. 109. 109. id="p-109" id="p-109" id="p-109" id="p-109" id="p-109" id="p-109" id="p-109"
id="p-109"
[000109] Secondary Pharmacodvnamics 110. 110. 110. id="p-110" id="p-110" id="p-110" id="p-110" id="p-110" id="p-110" id="p-110"
id="p-110"
[000110] In Vitro Radio-Ligand Receptor and Enzyme Assays 111. 111. 111. id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111" id="p-111"
id="p-111"
[000111] The binding potential of 18-MC with 64 neurotransmitter-related binding sites was evaluated (TABLE 2). 18-MC at 100 nM concentration had no binding activity to any of the receptors assayed. Binding was seen only to the adrenergic alpha—1 receptor, Mu opioid receptor, and sodium site 2 channel ligands at 10 uM, which is several orders of magnitude greater than the expected human plasma concentration of unbound 18-MC.
TABLE 2 Binding sites tested with 18-MC HCI in the radio-ligand assays NEUROTRANSMITTER RELATED Adenosine, Non-selective Adrenergic, Alpha 1, Non-selective Adrenergic, Alpha 2, Non-selective Adrenergic, Beta 1 Cannabinoid, CBI Cannabinoid, CB2 Dopamine, D4.2 GABA A, Agonisl Site GABA A, BDZ, alpha 1 site GABA—B Glutamate, AMPA Site (lonotropic) Glutamate, Kainate Site (lonotropic) Glutamate, NMDA Agonist Site (lonotropic) Glutamate, NMDA, Phencyclldlne Site (lonotropic) Glutamate, mGluRl (Metabotropic) Glutamate, mGluR5 (Metabotropic) Glutamate, NMDA, Glycine (Strychnine—insen) Glycine, Strychnine—sensitive Histamine, Hl Histamine, H2 Histamine, H3 Muscarinlc, Ml Muscarinic, M2 Muscarinic, Non-selective, Peripheral Nicotinic, Muscle (a—BnTx sensitive) Nicotinic, Neuronal (a—BnTx insensitive) Opioid, Kappa 1 Opioid, Mu STEROIDS Estrogen NR3Al Glucocorticoid Testosterone (cytosolic) ION CHANNELS Calcium Channel, Type L (Benzothiazepine Site) Calcium Channel, Type L (Dihydropyridine Site) Calcium Channel, Type N Potassium Channel, ATP—Sensitive Potassium Channel, Ca2+ Act., VI Sodium, Site 2 SECOND MESSENGERS Nitric Oxide, NOS (Neuronal—Binding) PROSTAGLANDINS Leukotriene, LTB4 (BLT) Leukotriene, LTD4 (CysLT1) Thromboxane A2 GROWTH FACTORS/HORMONES Corticotropin Releasing Factor, Non-selective Oxytocin Platelet Activating Factor, PAF Thyrotropin Releasing Hormone, TRH BRAIN/GUT PEPTIDES Angiotensin II, AT1 Angiotensin II, AT2 Bradykinin, BK2 Cholecystokinin, CCK1 (CCKA) Cholecystokinin, CCK2 (CCKB) Endothelin, ET—A Endothelin, ET—B Galanin, Non—Selective Neurokinin, NKI Neurokinin, NK2 (NKA) Neurokinin, NK3 (NKB) Vasoactive Intestinal Peptide, Non-selective Vasopressin 1 ENZYMES Decarboxylase, Glutamic Acid Esterase, Acetylcholine Oxidase, MAO-A, Peripheral Oxidase, MAO-B, Peripheral Transferase, Choline Acetyl 17 WO 2021/067549 PCT/US2020/053726 112. 112. 112. id="p-112" id="p-112" id="p-112" id="p-112" id="p-112" id="p-112" id="p-112"
id="p-112"
[000112] EXAMPLE 3 113. 113. 113. id="p-113" id="p-113" id="p-113" id="p-113" id="p-113" id="p-113" id="p-113"
id="p-113"
[000113] Safety Pharmacology 114. 114. 114. id="p-114" id="p-114" id="p-114" id="p-114" id="p-114" id="p-114" id="p-114"
id="p-114"
[000114] To assess the effects of 18-MC HCI upon the central nervous, respiratory, and cardiovascular systems, a series of studies were conducted according to FDA and ICH guidance. In vitro studies (hERG ionic conductance and action potential duration in rabbit cardiac purkinje fibers) were performed to evaluate potential effects upon cardiac electrophysiology, and in vivo studies were performed in the rat and monkey to evaluate effects upon behavior and pulmonary and cardiovascular function. As no sex-specific effects were anticipated based upon prior data, the in vivo studies employed only one sex (males). The in vitro rabbit purkinje and in vivo safety pharmacology studies were conducted under GLP regulations. 115. 115. 115. id="p-115" id="p-115" id="p-115" id="p-115" id="p-115" id="p-115" id="p-115"
id="p-115"
[000115] In Vitro Safety Pharmacology 116. 116. 116. id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116" id="p-116"
id="p-116"
[000116] In Vitro hERG Channel Inhibition Assav [OOO117] The potential for 18-MC to inhibit the hERG potassium channel was evaluated in a stably transfected Chinese Hamster Ovary (CHO) cell line expressing hERG mRNA (FIGURE 12). The |C5o was 1.46 uM. Since this result is considered a moderate risk for QT prolongation, a more sensitive test (which measures action potential depolarization in whole Purkinje fibers isolated from rabbit heart) was performed. Cells were voltage clamped at a holding potential of -80 mV. The hERG current was then activated by a depolarizing step (-50 mV for 300 ms) and repeated every 12 s. 18- MC was prepared from 10 mM methanol stock solutions. The hERG current inhibition was calculated from the average of 3 separate recordings. The |C5o is 1.6 uM. [0OO118] Action Potential Duration (APD) in Rabbit Cardiac Purkinie Fibers 119. 119. 119. id="p-119" id="p-119" id="p-119" id="p-119" id="p-119" id="p-119" id="p-119"
id="p-119"
[000119] The in vitro effect of 18-MC on the cardiac action potential was evaluated in isolated rabbit Purkinje fibers (FIGURE 13). FIGURE 13 shows superimposed records before (control) and after equilibration of the test article (0.3, 1, 3 and 10 pM 18-MC) using a 1 second base cycle length (BCL). Not shown was a positive control dl-Sotalol (50 (AM) significantly prolonged (~40%) APDeo and APD90. Fibers with resting potentials more negative than -80 mV and normal action potential morphology (APD9o 2 150 ms) were used in the study. Fibers were stimulated continuously at BCL of 1 second for at least 5 minutes. At the end of this period, baseline control APD rate dependence was measured using stimulus pulse trains consisting of approximately 50 pulses at BCL of 1 and 0.5 seconds. After returning to BCL of 1 second, 18-MC (or dl-sotalol) at the lowest concentration was applied for at least 20 minutes to allow equilibration, and the stimulus trains repeated. The entire sequence (~20 minutes of equilibration followed by stimulus trains at decreasing BCL) was repeated at cumulatively increased 18-MC concentration. The average responses from the last five recorded action potentials from each stimulus train were analyzed for each test condition. 18 WO 2021/067549 PCT/US2020/053726 120. 120. 120. id="p-120" id="p-120" id="p-120" id="p-120" id="p-120" id="p-120" id="p-120"
id="p-120"
[000120] Electrophysiological recordings were performed with four nominal concentrations of 18-MC (0.3, 1, 3, and 10 (M) added sequentially to four preparations at two stimulus intervals (basic cycle lengths of 1s and O.5s). The effects of 18-MC on action potential parameters were compared to time-matched vehicle control sequences. 18-MC did not prolong the QT interval at any concentration tested. However, at 3 uM, 18-MC induced statistically significant (p <0.05) shortening of the action potential duration (APD)eo at 1 second base cycle length (BCL). 18-MC at 10 uM induced statistically significant (P <0.05) shortening of APDeo at 0.5 and 1s BCL. 18-MC did not induce significant changes (at any of the concentrations tested) in resting membrane potential (RMP), action potential amplitude (APA) or Vmax at two stimulus intervals. In summary, in isolated rabbit Purkinje fibers, 18- MC did not prolong the QT interval, but at concentrations of 8 (M and 10 (AM induced statistically significant shortening in action potential repolarization. 121. 121. 121. id="p-121" id="p-121" id="p-121" id="p-121" id="p-121" id="p-121" id="p-121"
id="p-121"
[000121] In Vivo Safety Pharmacology 122. 122. 122. id="p-122" id="p-122" id="p-122" id="p-122" id="p-122" id="p-122" id="p-122"
id="p-122"
[000122] Central Nervous System: Modified Irwin Test Following Oral Administration of 18-MC HCI to Sprague Dawley Rats 123. 123. 123. id="p-123" id="p-123" id="p-123" id="p-123" id="p-123" id="p-123" id="p-123"
id="p-123"
[000123] The effects of orally administered 18-MC HCI on the gross behavioral, physiological, and neurological states were evaluated in two studies in Sprague Dawley rats using a modification of a primary observation test, the modified Irwin test. 124. 124. 124. id="p-124" id="p-124" id="p-124" id="p-124" id="p-124" id="p-124" id="p-124"
id="p-124"
[000124] A pilot dose finding study was performed in female rats receiving a single oral dose of 30- 800 mg/kg 18-MC HCI in different formulations. Under the conditions of this study, the no-observed- effect level (NOEL) and no-observed-adverse-effect level (NOAEL) were considered to be 90 mg/kg and 400 mg/Kg, respectively. 125. 125. 125. id="p-125" id="p-125" id="p-125" id="p-125" id="p-125" id="p-125" id="p-125"
id="p-125"
[000125] A second, definitive GLP study was performed in male rats receiving a single oral dose of O, 200, 400 and 600 mg/kg 18-MC HCI. The objective of this study was to evaluate the effects of a single dose of 18-MC HCI, orally administered, on the gross behavioral, physiological, and neurological state of male Sprague Dawley rats using a modification of a primary observation test, specifically the Irwin test. Only male rats were utilized in the assay, as no significant sex-specific effects have been noted in prior toxicology studies. 126. 126. 126. id="p-126" id="p-126" id="p-126" id="p-126" id="p-126" id="p-126" id="p-126"
id="p-126"
[000126] Vehicle (5% dextrose, pH 3) or 18-MC HCI in the vehicle (adjusted to pH 3) was administered as a single oral dose by gavage at 0, 200, 400, or 600 mg/kg, respectively, to 4 groups (Groups 1 through 4) of 6 male Sprague Dawley rats/group. The dose volume for all groups was mL/kg. Observations for the Irwin test were performed pre-dose (on the day of dosing) and at approximately (: 5 minutes) 30, 90, 150, and 240 minutes post-dosing. Body temperature was measured and recorded during each Irwin observation period. 127. 127. 127. id="p-127" id="p-127" id="p-127" id="p-127" id="p-127" id="p-127" id="p-127"
id="p-127"
[000127] Neurobehavioral findings judged as minimal in severity and generally consistent with the 19 WO 2021/067549 PCT/US2020/053726 intended pharmacological activity of the test article, a central or3[34 nicotinic receptor antagonist that attenuates dopaminergic transmission (Szumlinski er. a/., 2000), were noted as early as 30 minutes post-administration. As shown in TABLE 3, the predominant observations (ones that occurred in at least half the animals in the mid— and/or high-dose groups at a given time point) were an increased incidence of passivity and abnormal gait (waddling and/or walking low on limbs). Other obsen/ations consisted of decreased locomotor activity, decreased alertness, slower respiration rate, decreased cutaneous blood flow, and/or increased pupil diameter. The findings appeared to be dose-dependent noted primarily in animals of the higher dose groups in which increased frequency and occurrence corresponded to increased dose. Observations at the 200 mg/kg dose were limited to isolated occurrences (one animal at a given time point) of passivity, increased touch response, reduced locomotor activity, and/or increased pupil diameter. The time of peak effect of the observations appeared to occur between 90 and 150 minutes post—dosing. A dose-dependent decrease in body temperature was also noted (mean decreases from pre-dose values of up to 1.5, 2.3, and 2.390 in the 200, 400, and 600 mg/kg groups, respectively) and peaked at approximately 90 minutes post—dosing.
By 240 minutes post—dose, the number of animals with observations and the frequency and severity of observations was reduced in 18-MC HCI-treated animals relative to that seen at earlier time points.
TABLE 3 Summary of Irwin test parameter occurrences Total Occurrence(s /No. of Males (Within Observation Period") Finding Group 1 Group 2 Group 3 Group 4 Control 200 mg/kg 400 mg/kg 600 mgfig Decreased locomotor 1/6 (90) 2/6 (90, 150) 2/6 (30, 90, 150, 240) activity Passivity 1/6 (90, 1/6 (30, 90,150, 240) 1/6 (30, 90, 240) 1/6 (pre) 240) 3/6 (150) 2/6 (240) 3/6 (30, 90) 4/6 (150) Decreased alertness 1/6 (30) 1/6 (150, 240) 2/6 (30, 90) Slower respiration rate 1/6 (90, 150, 240) 1/6 (90, 150) Abnormal gait (waddling) 1/6 (30, 150) 1/6 (240) 2/6 (90) 2/6 (30) 3/6 (150) 4/6 (90) Abnormal gait (walking 1/6 (90) 1/6 (30) low on limbs) Increased touch response 1/6 (pre, 30) 1/6 (pre) Increased pupil diameter 1/6 (30) 1/6 (150) 1/6 (90) 2/6 (30, 90) Decreased cutaneous 1/6 (30, 90, 150) blood flow Diarrhea 1/6 (240) WO 2021/067549 PCT/US2020/053726 128. 128. 128. id="p-128" id="p-128" id="p-128" id="p-128" id="p-128" id="p-128" id="p-128"
id="p-128"
[000128] 3 Observation periods include prior to dosing; 30, 90, 150, and 240 minutes post-dosing 129. 129. 129. id="p-129" id="p-129" id="p-129" id="p-129" id="p-129" id="p-129" id="p-129"
id="p-129"
[000129] In conclusion, oral administration of 18-MC HCI in male Sprague Dawley rats was associated with dose-dependent neurobehavioral observations generally consistent with its intended pharmacological activity. The effects were predominantly noted at doses 2400 mg/kg and peaked 90- 150 minutes post-dosing, subsiding in occurrence by 240 minutes post—administration. 130. 130. 130. id="p-130" id="p-130" id="p-130" id="p-130" id="p-130" id="p-130" id="p-130"
id="p-130"
[000130] Cardiovascular and Respiratory System: Radiotelemetrv Assessment Following Nasoqastric Administration of 18-MC HCI to Conscious Cvnomolqus Monkevs 131. 131. 131. id="p-131" id="p-131" id="p-131" id="p-131" id="p-131" id="p-131" id="p-131"
id="p-131"
[000131] The potential acute effects of 18-MC HCI were evaluated in conscious radiotelemetry- instrumented male cynomolgus monkeys following nasogastric dosing of 0, 30, 90 or 270 mg/kg in a GLP study. Animals were assigned in a latin—square cross—over design and received a single dose of 18-MC HCI between each wash-out period of approximately 7 days. Arterial blood pressure, heart rate, body temperature, lead ll electrocardiogram (ECG), and respiratory parameters were recorded continuously for approximately 1 hour prior to administration of vehicle or 18-MC HCI through approximately 24 hours post-dosing. Clinical observations were performed at approximately 4 and 24 hours post-dosing. 132. 132. 132. id="p-132" id="p-132" id="p-132" id="p-132" id="p-132" id="p-132" id="p-132"
id="p-132"
[000132] Single oral administration of 18-MC HCI at doses of 30, 90, or 270 mg/kg to male radiotelemetry-implanted cynomolgus monkeys did not affect cardiovascular parameters (i.e. heart rate, blood pressure [systo|ic, diastolic, or mean arterial], pulse pressure, ECG waveform morphology, or ECG intervals [PR, QRS, RR, QT, or QTcB]), body temperature, or respiratory parameters (respiratory frequency, tidal volume, or minute volume). Emesis occurred in some of the animals dosed with 270 mg/kg 18-MC HCI. There were no other drug-related clinical findings. The NOEL on the cardiovascular and respiratory systems was 270 mg/kg 18-MC HCI, the highest dose tested. 133. 133. 133. id="p-133" id="p-133" id="p-133" id="p-133" id="p-133" id="p-133" id="p-133"
id="p-133"
[000133] Cardiovascular System: Radiotelemetrv Assessment Followinq Oral Administration of 18- MC HCI to Conscious CD-1 Mice 134. 134. 134. id="p-134" id="p-134" id="p-134" id="p-134" id="p-134" id="p-134" id="p-134"
id="p-134"
[000134] The potential acute effects of oral administration of 18-MC HCI on arterial blood pressure, heart rate, and body temperature was assessed in conscious male CD-1 mice by radiotelemetry- instrumentation in a non-GLP acute dosing study. Other studies showed lethality at lower oral doses of 18-MC HCI (100 mg/kg or less) in mice. The purpose of this study was to explore the physiological changes associated with mortality. Animals were implanted with a radiotelemetry transmitter in the peritoneal cavity with the catheter inserted in the femoral artery and the sensor tip positioned in the abdominal aorta. Six animals were each administered an oral dose of 100 mg/kg and, 8 hours later, 200 mg/kg 18-MC HCI in 5% dextrose (pH 3). Two of the 6 animals died after receiving the 100 mg/kg dose and all of the other animals died after the 200 mg/kg dose. Within one hour of dosing, average heart rate (FIGURE 14) decreased about 50%, and significant decreases in systolic (FIGURE 15) and 21 WO 2021/067549 PCT/US2020/053726 diastolic blood pressure (FIGURE 16). In addition, body temperature generally dropped at each collection time point, reaching a maximum difference from baseline at 120 minutes post-dose (average change up to 65°C). Following administration of the 200 mg/kg dose, body temperature continued to drop (up to 105°C) until all mice died (~12 hours post-dose). These changes in body temperature were considered test article—related and correlated to the observed changes in heart rate. Terminally, there was a further decrease in all of the parameters, with the rectal temperatures falling to as low as 22 °C before the mice died. Observed effects on behavior and activity included tremors, twitches, abnormal gait, lethargy, decreased motor activity, increased response to touch and startle, seizures, gasping and slow respirations, exophthalmia, and stupor. The peak effects occurred between 90 and 150 minutes after the oral administration of 18—MC HCI. 135. 135. 135. id="p-135" id="p-135" id="p-135" id="p-135" id="p-135" id="p-135" id="p-135"
id="p-135"
[000135] Lethal or near lethal oral doses of 18—MC HCI were associated with reductions in body temperature, heart rate and blood pressure. Differences from baseline were initially noted 1-2 hours post-administration and may reflect direct or indirect effects related to 18—MC HCI anticipated pharmacologic activity. 136. 136. 136. id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136" id="p-136"
id="p-136"
[000136] Based upon the results of this and the 2-week mouse toxicology study (where milder effects on body temperature were seen at a dose of 50 mg/kg), vital signs (including body temperature) can be closely monitored as part of the clinical trial. The effects seen in this study were not noted in the monkey cardiovascular safety pharmacology study suggesting the reductions observed may be species specific. 137. 137. 137. id="p-137" id="p-137" id="p-137" id="p-137" id="p-137" id="p-137" id="p-137"
id="p-137"
[000137] EXAMPLE 4 138. 138. 138. id="p-138" id="p-138" id="p-138" id="p-138" id="p-138" id="p-138" id="p-138"
id="p-138"
[000138] Pharmacokinetics and Metabolism in Animals 139. 139. 139. id="p-139" id="p-139" id="p-139" id="p-139" id="p-139" id="p-139" id="p-139"
id="p-139"
[000139] The pharmacokinetics and metabolism of 18—MC HCI have been studied in a range of animal and human models. The key findings are summarized below. 140. 140. 140. id="p-140" id="p-140" id="p-140" id="p-140" id="p-140" id="p-140" id="p-140"
id="p-140"
[000140] 18—MC is rapidly absorbed and distributed into the brain and fat tissues in rats dosed with 40 mg/kg p.o. or i.p. The estimated volume of distribution is 8 L/kg. 18—MC levels in fat were 4.2 uM and 2.5 uM at 2 hours and 24 hours, respectively. 18—MC HCI is extensively metabolized in vitro and in vivo with up to 13 metabolites identified. On oral administration, it appears that the major metabolites are either M4 or M5, depending on the animal species tested. M4 and M5 are the primary circulating drug species because they are present at proportions greater than 18—MC. 18—MC HCI has relatively low oral bioavailability in the rat (about 8% after the administration of 60 mg/kg). The oral bioavailability for total drug substance (AUC of 18—MC and its metabolites) is about 25% after the administration of 60 mg/kg in the rat. 18—MC HCI moderately inhibits CYP2C9 and CYP2Cf9 (<1.5 uM), and less so for CYP2C8, CYP2E1 and CYP3A4. 18—MC shows multi—compartmental elimination following oral administration. In the animal species tested its half-life is less than 2 hours at lower 22 WO 2021/067549 PCT/US2020/053726 doses. At high doses a long elimination phase is evident (ranging from 9 to 20 hours in rats). 18—MC is highly protein bound (95-98%). 141. 141. 141. id="p-141" id="p-141" id="p-141" id="p-141" id="p-141" id="p-141" id="p-141"
id="p-141"
[000141] In Vitro Metabolite Profilino in Hepatocytes 142. 142. 142. id="p-142" id="p-142" id="p-142" id="p-142" id="p-142" id="p-142" id="p-142"
id="p-142"
[000142] This study evaluated in vitro metabolism of 18—MC HCI in hepatocytes prepared from livers of mouse, rat, dog, monkey and human. Following incubation of 18—MC HCI 10 uM in hepatocytes, 13 potential metabolites were found by liquid chromatography/mass spectrometry (LC/MS). The relative abundance of the metabolites was determined by the area under the curve of the peak heights. Metabolites with AUC greater than 10% of all drug-related material are considered major, and these are M2, M4, M5, M8, M9, and P2. [00O143] Exposure from the 14-Day Mouse Toxicokinetic Study 144. 144. 144. id="p-144" id="p-144" id="p-144" id="p-144" id="p-144" id="p-144" id="p-144"
id="p-144"
[000144] A 14-day oral gavage toxicity study of 18—MC HCI was conducted in CD-1 mice with a 14- day recovery period. The relative metabolite concentrations were determined from plasma samples obtained on the last day of dosing in the 25 mg/kg/day group of animals using a UPLC/MS/MS method. Major metabolites were identified as M2 and M4, followed by M8 and M9. The parent 18—MC exposure was less than 1% of the total drug related material. No significant sex differences were observed. 145. 145. 145. id="p-145" id="p-145" id="p-145" id="p-145" id="p-145" id="p-145" id="p-145"
id="p-145"
[000145] The 18—MC pharmacokinetic parameters demonstrated with an increase in the dose there was an increase in the 18—MC exposure. The parameters after the first and last day of dosing were similar and there was no consistent sex difference after 25 mg/kg but the female exposure appeared lower compared to the males with the higher doses. [0OO146] Pharmacokinetics in 14-Day Monkey Study 147. 147. 147. id="p-147" id="p-147" id="p-147" id="p-147" id="p-147" id="p-147" id="p-147"
id="p-147"
[000147] In a 14-day 18—MC HCI toxicology study in the cynomolgus monkey with a 4-week recovery period, the relative metabolite concentrations were determined from plasma samples obtained on the last day of dosing (Day 14) in the high dose group. The animals received 400 mg/kg on Day 1 and thereafter 300 mg/kg/day. The relative concentrations of the metabolites and 18—MC were determined by the peak-heights by UPLC/MS/MS method. Major metabolites were identified as M5>>M2>>P2. Metabolite M4 was on the borderline to be considered a major metabolite. The parent 18—MC exposure was less than 3% of the total drug and metabolite exposure. 148. 148. 148. id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148" id="p-148"
id="p-148"
[000148] Generally the 18—MC exposure was independent of sex. The exposure increased less than proportional with the dose, being more noticeable between the middle and high dose groups.
There was no accumulation of 18—MC when the parameters on the first and last day of dosing are compared and instead the exposure appeared to decrease with repeat dosing. The absorption appeared to be rapid with the Tmax at the time of the first plasma sample (1 hour) in most animals. 149. 149. 149. id="p-149" id="p-149" id="p-149" id="p-149" id="p-149" id="p-149" id="p-149"
id="p-149"
[000149] Plasma Protein Binding Studies 23 WO 2021/067549 PCT/US2020/053726 150. 150. 150. id="p-150" id="p-150" id="p-150" id="p-150" id="p-150" id="p-150" id="p-150"
id="p-150"
[000150] 18-MC exhibited similar degree of protein binding, 92-98% on average, in all species tested (TABLE 4). There is no information on the protein binding of any of the metabolites.
TABLE 4 Protein Binding in Difference Species Species Target Concentration %Bound Mean Average (ng/mL) 1 SD %Bound Mean 1 SD Mouse 200 97.0 1 0.208 600 97.1 1 0.058 96.9 1 0.321 ,000 96.5 1 0.071 Rat 200 92.9 1 0.351 600 94.9 1 0.794 92.7 1 2.36 ,000 90.2 1 0.153 Dog 200 92.1 11.78 600 94.8 1 1.42 93.4 1 1.36 ,000 93.2 1 0.153 Monkey 200 98.4 1 0.643 600 97.7 1 0.100 97.8 1 0.603 ,000 97.2 1 0.100 Human 200 96.8 1 0.321 600 97.6 1 0.153 96.5 11.22 ,000 95.2 1 0.473 [00O151] In Vitro Inhibition of Human Cytochrome P450 lsoenzvmes by 18-MC HCI 152. 152. 152. id="p-152" id="p-152" id="p-152" id="p-152" id="p-152" id="p-152" id="p-152"
id="p-152"
[000152] The potential for 18-MC to inhibit metabolic isozymes was evaluated with recombinant human CYP enzymes 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 (TABLE 5). Control incubations were performed for each assay with appropriate positive inhibitory controls. There is no data on the inhibitory potential of any of the metabolites on the isozymes.
TABLE 5 Summary of |C5o values lsoform IC5o (HM) 18-MC Positive Control CYP1 A2 N I 4.2 CYP2A6 NI 1 .5 CYP2B6 >1 00 0.2 CYP2C8 1 9 0.4 CYP2C9 4.1 0 .4 CYP2C1 9 4.9 1 .5 CYP2D6 >100 0.01 CYP2E1 28 0.8 CYP3A4-BFC 13 0.01 CYP3A4-DBF NI 0.002 NI = No inhibition detected 153. 153. 153. id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153" id="p-153"
id="p-153"
[000153] EXAMPLE 5 [O00154] Toxicology 24 WO 2021/067549 PCT/US2020/053726 155. 155. 155. id="p-155" id="p-155" id="p-155" id="p-155" id="p-155" id="p-155" id="p-155"
id="p-155"
[000155] 14-Dav Oral Gavade Toxicity in CD-1 Mice with a 14-Dav Recoverv Period 156. 156. 156. id="p-156" id="p-156" id="p-156" id="p-156" id="p-156" id="p-156" id="p-156"
id="p-156"
[000156] The potential toxicity and toxicokinetic profile of 18-MC HCI was investigated in a GLP study in which 18-MC HCI was administered daily by oral gavage to CD-1 mice for 14 consecutive days and evaluated the recovery, persistence, or progression of any effects following a minimum of a 14-day recovery period. 157. 157. 157. id="p-157" id="p-157" id="p-157" id="p-157" id="p-157" id="p-157" id="p-157"
id="p-157"
[000157] Study Methods 158. 158. 158. id="p-158" id="p-158" id="p-158" id="p-158" id="p-158" id="p-158" id="p-158"
id="p-158"
[000158] This study was designed to assess the toxicological effects of 18-MC HCI in CD-1 mice when dosed at O, 25, 50, or 100 mg/kg/day for 14 days by oral gavage following a 2 to 4 day dose up- titration regimen, with expanded assessments of potential neurotoxicity and a 14 day recovery segment (TABLE 6).
TABLE 6 Study Design 2-Week Mouse Study Group Treatment Dosage Dose Volume Number of Animalsa""° Number Level (mL/kg) (mg/kg/day) Males Females 1 Vehicle Control 0 10 25 25 2 18-MC HCI 25 10 20 20 3 18-MC HCI 50 10 20 20 4 18-MC HCI 100 10 25 25 159. 159. 159. id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159" id="p-159"
id="p-159"
[000159] aGroup 1, vehicle (5% dextrose, pH 3.0), was dosed for 18 consecutive days (study days - 4 through 13), which corresponded to Group 4. Group 2 was dosed with 12.5 mg/kg/day (study days - 2 and -1) and 25 mg/kg/day (study days 0 through 13). Group 3 was dosed with 12.5 mg/kg/day (study day -3), 25 mg/kg/day (study day -2), 37.5 mg/kg/day (study day -1 ), 50 mg/kg/day (study days 0 through 13). Group 4 was dosed with 12.5 mg/kg/day (study day -4), 25 mg/kg/day (study day -3), 50 mg/kg/day (study day -2), 75 mg/kg/day (study day -1), and 100 mg/kg/day (study days 0 through 13). 160. 160. 160. id="p-160" id="p-160" id="p-160" id="p-160" id="p-160" id="p-160" id="p-160"
id="p-160"
[000160] b 15 animals/sex/group were selected for the primary necropsy, with 10 animals/sex/group used for necropsy, clinical pathology, organ weight, and microscopic evaluation, and 5 animals/sex/group perfused for neuropathology assessment. 161. 161. 161. id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161" id="p-161"
id="p-161"
[000161] 0 The remaining 5 or 10 animals/sex/group were euthanized following a 14-day nondosing (recovery) period, with 5 animals/sex/group used for necropsy, clinical pathology, organ weight, and microscopic evaluation, and the remaining 5 animals/sex in the control and 100 mg/kg/day groups perfused for neuropathology assessment. 162. 162. 162. id="p-162" id="p-162" id="p-162" id="p-162" id="p-162" id="p-162" id="p-162"
id="p-162"
[000162] All test article-treated animals underwent up-titration of dosage levels prior to reaching the maximum daily dose, which was administered for 14 consecutive days. The up-titration was performed because earlier studies indicated that tolerability may have been improved by slowly WO 2021/067549 PCT/US2020/053726 ramping up the dose. The dose volume was 10 mL/kg for all groups. Groups 1 and 4 each consisted of 25 animals/sex and Groups 2-3 each consisted of 20 animals for each sex. Following 14 days of dose administration, 15 mice/sex/toxicology group were euthanized; the remaining 5, (10for the control and high dose group) mice/sex/toxicology group were euthanized following a 14-day nondosing (recovery) period. Following the final blood collection (study day 13), all toxicokinetic animals (from a satellite group of 18 animals/sex/dose level) were euthanized. 163. 163. 163. id="p-163" id="p-163" id="p-163" id="p-163" id="p-163" id="p-163" id="p-163"
id="p-163"
[000163] For toxicology assessment, all animals were observed twice daily for mortality and moribundity. Clinical observations were recorded daily, and detailed physical examinations were conducted weekly. Body weights and food consumption were recorded twice weekly. Body temperature was recorded prior to dosing and following dosing at the time that post—dosing clinical observations were conducted. Functional observational battery (FOB) data were recorded for all animals near the start of the treatment period, near the end of the treatment period, and near the end of the recovery period. Ophthalmic examinations were performed during pretest and near the end of the dosing period. At the primary necropsy 10 animals/sex/group and at the recovery necropsy 5 animals/sex/group, were selected for complete necropsies, clinical pathology assessment (hematology and serum chemistry), organ weight collection, and microscopic examination of a full list of tissues. At each termination interval, 5 animals/sex/group were assigned for neuropathology assessments that involved perfusion fixation, comprehensive sectioning of the brain and collection of selected peripheral nerves, and the employment of special stains used to detect subtle neuronal injury. 164. 164. 164. id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164" id="p-164"
id="p-164"
[000164] Toxicology Results 165. 165. 165. id="p-165" id="p-165" id="p-165" id="p-165" id="p-165" id="p-165" id="p-165"
id="p-165"
[000165] One male assigned to the 100 mg/kg/day group was found dead on study day -1 during the up—tltration period, following 4 doses (12.5, 25, 50, and 75 mg/kg/day) and exhibited no significant clinical signs. Another male was found dead on study day 12, with clinical findings of clonic convulsions, hypoactivity, splayed hindlimbs, and decreased respiration. The death of the male that exhibited the clinical signs was considered test article related, whereas the relationship of test article to the other ma|e’s death was less certain. There were no microscopic, macroscopic, or clinical observation findings that definitively determined a cause of death of either animal. Specifically, the causes of death for these males were undetermined microscopically although both had atrial and/or left ventricular dilatation noted in the heart. These findings were not observed in any animals that survived to the scheduled necropsies and as such are not clearly directly related to test article administration. 166. 166. 166. id="p-166" id="p-166" id="p-166" id="p-166" id="p-166" id="p-166" id="p-166"
id="p-166"
[000166] Two females were found dead (one control and one treated with 50 mg/kg/day on study days 4 and 2, respectively). Both deaths were unrelated to test article; the death of the 50 mg/kg/day 26 WO 2021/067549 PCT/US2020/053726 female was attributable to trauma. 167. 167. 167. id="p-167" id="p-167" id="p-167" id="p-167" id="p-167" id="p-167" id="p-167"
id="p-167"
[000167] All other main study animals survived to the scheduled necropsies. 168. 168. 168. id="p-168" id="p-168" id="p-168" id="p-168" id="p-168" id="p-168" id="p-168"
id="p-168"
[000168] In addition to the findings in the one 100 mg/kg/day male that died on Day 12, test article- related clinical observations were noted at approximately 1 hour following dose administration during the dosing period and included soft stool for males in the 50 mg/kg/day group and males and females in the 100 mg/kg/day group. In addition, findings of a cool body, brown material around the anogenital area, and diarrhea were noted sparingly for males in the 100 mg/kg/day group. 169. 169. 169. id="p-169" id="p-169" id="p-169" id="p-169" id="p-169" id="p-169" id="p-169"
id="p-169"
[000169] There was no test article related findings in: body weights; food consumption; home cage, handling, open field, sensory, or neuromuscular observations; or organ weights. There were no toxicologically significant test article—related alterations in hematology, bone marrow cytology, serum chemistry, or ophthalmic examinations. There were no test article—related changes in the neuropathology gross necropsy, brain weights or measurements, or microscopic evaluation. [0O0170] There were physiological changes in body temperature. Mean body temperatures for males and females in the 100 mg/kg/day group were lower than the control group at 1 hour post- closing on study day 0; the difference in males was significant (p<0.05). At 1 hour post—dosing on study day 13, significantly (p<0.01 or p<0.05) lower body temperature was noted for males in the 50 and 100 mg/kg/day groups and females in the 100 mg/kg/day group. These findings were considered test article related but non-adverse and corresponded to clinical findings of cool body.
[OOO171] Toxicokinetic Results 172. 172. 172. id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172" id="p-172"
id="p-172"
[000172] Toxicokinetic parameters are presented in TABLE 7.
TABLE 7 Summary of Toxicokinetic Parameters of 18-MC HCI Day Sex Male Female 18-MC HCI Dose 25 50 100 25 50 100 (mafia/day) 0 Cmax, ng/mL 19.4 44.3 131 30.8 23.7 51.8 Tmax, h 0.500 0.500 1.00 0.500 0.500 1.00 T1/2, h NC NC NC NC NC NC AUC(0-24), ng-h/mL 66.6 108 349 77.8 56.2 187 Cmax Ratio (Male/Female) 0.630 1.87 2.53 AUC(0-24) Ratio (Male/Female) 0.856 1.92 1.87 — — — 13 Cmax, ng/mL 23.6 92.9 136 25.6 49.9 44.0 Tmax, h 0.500 0.500 0.500 0.500 0.500 0.500 T1/2, h NC 1.78 1.93 NC NC 2.45 AUC(o—24), ng-h/mL 50.5 164 329 54.5 119 188 Crnax Ratio (Male/Female) 0.922 1.86 3.09 AUC(0_24) Ratio (Male/Female) 0.927 1.38 1.75 — — — Crnax Ratio (Day 13/Day 0) 1.22 2.10 1.04 0.831 2.11 0.849 AUC(o.24) Ratio (Day 13/Day 0) 0.758 1.52 0.943 0.701 2.12 1.01 27 WO 2021/067549 PCT/US2020/053726 173. 173. 173. id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173" id="p-173"
id="p-173"
[000173] In general, 18-MC exposure (Cmax and AUC(o-24)) increased with dose in both sexes for the single and repeated doses. The exposure in males was higher than females on both study days.
There was no apparent accumulation of 18-MC in mice following repeated daily dosing for 14 days, which is consistent with the short half-life of 18-MC.
[OOO174] 18-MC HCI was administered orally by gavage once daily for 14 consecutive days to 3 toxicological groups (Groups 2-4) and 3 toxicokinetio groups (Groups 2A—4A) of Cr|:CD1(|CR) mice.
Mortality was noted for one male in the 100 mg/kg/day group during the treatment phase. A cause of death of this animal was not determined microscopically but exaggerated pharmacological effects of the test article (clonic convulsions, hypoactivity, splayed hindlimbs, and decreased respiration) were noted prior to death. Therefore, a dosage level of 50 mg/kg/day was considered as the no—observed— adverse-affect level (NOAEL) for males and 100 mg/kg/day for females, corresponding to AUC(o-24) values of 164 ngxh/mL and 188 ngxh/mL, respectively, on study day 13. With the exception of a non- adverse decreased body temperature in males and females at 50 and 100 mg/kg/day, there were no noted neurobehavioral findings as measured in the Functional Observational Battery. 175. 175. 175. id="p-175" id="p-175" id="p-175" id="p-175" id="p-175" id="p-175" id="p-175"
id="p-175"
[000175] 14-Day Oral Gavaqe Toxicity and Toxicokinetics in Monkeys with a 4—Week Recovery M 176. 176. 176. id="p-176" id="p-176" id="p-176" id="p-176" id="p-176" id="p-176" id="p-176"
id="p-176"
[000176] The toxicokinetics and toxicity profile of 18-MC HCI was investigated in a GLP study in which 18-MC HCI was administered daily for 14 consecutive days to cynomolgus monkeys. 177. 177. 177. id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177" id="p-177"
id="p-177"
[000177] Young adult male and female cynomolgus monkeys were administered 18-MC HCI by nasogastric gavage for 14 consecutive days at doses of 0 (vehic|e=5% dextrose, pH=3), 50, 150, or 400/300 mg/kg/day. Due to severe clinical observations seen on the first day of dosing in the high dose group, the dose was subsequently reduced from 400 to 300 mg/kg/day. The study design is summarized in TABLE 8 below.
TABLE 8 Study Design of the 2—Week Monkey Study Group Dose Level Dose Dose Concentration No. of Animals No. of Animals No. (mg/kg/day) Volume (mg/mL) Primary necropsy Recovery (mL/kg) necropsy Male Female Male Female 1 0 10 0 3 3 2 2 2 50 10 5 3 3 2 2 3 150 10 15 3 3 2 2 45‘ 400/300 7.5/10 40/30 3 3 2 2 178. 178. 178. id="p-178" id="p-178" id="p-178" id="p-178" id="p-178" id="p-178" id="p-178"
id="p-178"
[000178] ’=‘ Beginning on Day 2 (second day of dosing), the dose volume was decreased from 10 mL/kg to 7.5 mL/kg in order to reduce the dose level of the high dose group to 300 mg/kg/day due the severity of clinical observations seen on Day 1. On Day 8, the dose volume was raised to 10 mL/kg and the dose concentration lowered to 30 mg/mL. 28 WO 2021/067549 PCT/US2020/053726 179. 179. 179. id="p-179" id="p-179" id="p-179" id="p-179" id="p-179" id="p-179" id="p-179"
id="p-179"
[000179] Assessments of neurobehavioral effects and general toxicity were based on mortality, functional observational battery (FOB) evaluations, clinical observations, body weight, and body temperature; ophthalmoscopic, electrocardiographic examinations; and anatomic and clinical pathology. The anatomical pathology evaluations included histopathology of a full list of tissues from all animals and a comprehensive evaluation of the central nervous system (including selected peripheral nerves) utilizing whole body perfusion and special stains. Bone marrow smears from all animals were evaluated microscopically. Complete differentials and myeloid-erythroid (ME) ratios were performed. Toxicokinetic assessment was conducted for the test article and metabolites. 180. 180. 180. id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180" id="p-180"
id="p-180"
[000180] There were no 18—MC—related ophthalmoscopic observation findings, alterations among urinalysis or, coagulation parameters in either sex at any dose level. No 18—MC—related findings among bone marrow parameters were observed in females at any dose. Findings in the neurological examinations were consistent with those reported as part of the clinical observations. No MC- 18-related microscopic findings were observed in the brain, spinal cord, phrenic nerves, or vagus nerves using hematoxylin and eosin, luxol fast blue, and fluro jade staining techniques. 181. 181. 181. id="p-181" id="p-181" id="p-181" id="p-181" id="p-181" id="p-181" id="p-181"
id="p-181"
[000181] There were no electrocardiographic changes that were directly attributable to administration of 18-MC HCI. One animal that died on Day 1 (see below) exhibited marked first degree AV block, an interventricular conduction disturbance and sinus bradycardia on the Day 1 post dose ECG. On Day 1, another high-dose animal that was sedated at the time of measurement had a wide complex tachycardia that was probably junctional tachycardia with aberrancy. The effects were likely indirect effects related to the marked clinical signs seen in this animal at the time of measurement. No electrocardiographic effects were seen in 18-MC HCI treated animals at the end of the treatment period. Consistent with the absence of electrocardiographic observations in all but the two animals mentioned above following treatment with 400 mg/kg. No cardiovascular findings were reported in the cardiovascular safety pharmacology study, in which telemetered monkeys were given doses as high as 270 mg/kg. 182. 182. 182. id="p-182" id="p-182" id="p-182" id="p-182" id="p-182" id="p-182" id="p-182"
id="p-182"
[000182] One male treated with 400 mg/kg died in exfremis immediately prior to a planned euthanasia in extremis due to 18—MC—related effects noted following dosing on Day 1. There were no 18—MC—related macroscopic or microscopic observations noted, however, and a cause of death for this animal could not be determined. Based on this death, the dose level for this group was subsequently decreased to 300 mg/kg/day (effective on Day 2) for the remainder of the dosing period. 183. 183. 183. id="p-183" id="p-183" id="p-183" id="p-183" id="p-183" id="p-183" id="p-183"
id="p-183"
[000183] 18—MC—related clinical signs noted at 400 mg/kg/day (Day 1) included eye |id(s) partially or completely closed, decreased activity, hunched posture, and salivation all with a low number of animals affected and low incidence. At 300 mg/kg/day, 18—MC—related clinical signs of decreased activity, ataxia, inappetence, salivation, hunched posture, emesis, vomitus, and eyelid 29 WO 2021/067549 PCT/US2020/053726 partially/completely closed were noted, all at low incidence. At 150 mg/kg/day, a few occurrences of decreased activity, inappetence, eyelid partially/completely closed were noted in a small number of animals. 184. 184. 184. id="p-184" id="p-184" id="p-184" id="p-184" id="p-184" id="p-184" id="p-184"
id="p-184"
[000184] Additional signs noted occasionally at doses 250 mg/kg/day that were related to the administration of 18—MC were watery and/or soft feces, vomitus and/or emesis. 185. 185. 185. id="p-185" id="p-185" id="p-185" id="p-185" id="p-185" id="p-185" id="p-185"
id="p-185"
[000185] Mean body weight/body weight gain was slightly reduced in animals receiving 18—MC HCI.
In this regard, mean cumulative body gain (Days 1-14) in males/females were -0.042/+0.04 kg, -0.22/- 0.08 kg, -0.28/-0.12 kg and -0.23/-0.09 kg, respectively. 186. 186. 186. id="p-186" id="p-186" id="p-186" id="p-186" id="p-186" id="p-186" id="p-186"
id="p-186"
[000186] Hematological changes consisted of 18-MC-related mild to moderate decreases in red cell mass in both sexes at closes 2150 mg/kg/day that were associated with occasional reductions in reticulocytes. There were no meaningful effects on erythrocyte morphology. Mild decreases in total leukocytes (attributable to lymphoid and myeloid cells) were noted in males at 400/300 mg/kg/day and in females at all dose levels. TABLE 9 summarizes these hematological changes.
TABLE 9 Summary of Effects on Hematology Parametersa 50 m /k /day 150 mg/kg/day 400/300 mg/kg/day Parameter M F M F M F Hemoglobin NC NC -17% -19% -20% -17% Leukocytes NC -29% NC -33% -40% -45% Neutrophils NC -29% NC -36% -20% -47% Lymphocytes NC -26% NC -28% -45% -41% Monocytes NC NC NC -81% -84% -77% [OOO187] aChange relative to pretest mean; +: increase; -: decrease [O0O188] M = males; F = females; NC: no toxicologically relevant change [0O0189] Clinical chemistry changes were limited to mild decreases in alkaline phosphatase and total bilirubin in both sexes at all dose levels and mild decreases in phosphorus in females at doses 2150 mg/kg/day and sodium and chloride in males at doses 2150 mg/kg/day (TABLE 10). These changes were not considered to be of significant toxicological relevance. [0OO190] 18-MC-related macroscopic observations at terminal necropsy were limited to the thymus.
Mildly small thymus was observed at 50 mg/kg/day and at 400/300 mg/kg/day. The mildly small thymus correlated microscopically with test article-related generalized lymphoid depletion. 191. 191. 191. id="p-191" id="p-191" id="p-191" id="p-191" id="p-191" id="p-191" id="p-191"
id="p-191"
[000191] Organ weight findings at terminal necropsy were observed in the liver (increase) and thymus (decrease) at doses 250 mg/kg/day. These organ weight differences were associated with microscopic findings in the respective organs. The following table summarizes the differences in mean organ weight values between control and 18—MC HCI treated animals.
WO 2021/067549 PCT/US2020/053726 TABLE 10 Test Article-related Organ Weight Changes — Terminal Male and Female Percent Change Relative to Control Dose level 50 mg/kg/day 150 mg/kg/day 400/300 mg/kg/day Sex M F M F M F Number Examined 3 3 3 3 3 3 Liver (g) T26.36 T52.66a T48.43a T43.49a T65.9sa T50.04a Liver/BWt% T22.10 T51 .233 T55.92b T55.09b T69.67b T67.01b Liver/BrWt ratio T22.1 1 T47.26a T557911 T423021 T46.39 T58.79b Thymus (g) $35.06 $35.14 $47.41 $52.77 $78.63a $79.51a Thymus/BWt% $36.35 $32.52 $43.99 $49.41 $77.39a $77.62 Thymus/BrWt ratio $34.90 $37.01 $45.30 $52.39 $81.19* $78.17a [00O192] aSignificant|y different from control; (p<0.05) [O00193] bSignificant|y different from control; (p<0.01) 194. 194. 194. id="p-194" id="p-194" id="p-194" id="p-194" id="p-194" id="p-194" id="p-194"
id="p-194"
[000194] BWt — Body Weight 195. 195. 195. id="p-195" id="p-195" id="p-195" id="p-195" id="p-195" id="p-195" id="p-195"
id="p-195"
[000195] BrWt - Brain Weight 196. 196. 196. id="p-196" id="p-196" id="p-196" id="p-196" id="p-196" id="p-196" id="p-196"
id="p-196"
[000196] T — Increased 197. 197. 197. id="p-197" id="p-197" id="p-197" id="p-197" id="p-197" id="p-197" id="p-197"
id="p-197"
[000197] $ - Decreased 198. 198. 198. id="p-198" id="p-198" id="p-198" id="p-198" id="p-198" id="p-198" id="p-198"
id="p-198"
[000198] M — Male 199. 199. 199. id="p-199" id="p-199" id="p-199" id="p-199" id="p-199" id="p-199" id="p-199"
id="p-199"
[000199] F — Female 200. 200. 200. id="p-200" id="p-200" id="p-200" id="p-200" id="p-200" id="p-200" id="p-200"
id="p-200"
[000200] 18—MC-related microscopic findings were observed in the liver and thymus of male and female terminal animals at 250 mg/kg/day and the bone marrow (femur, rib, and sternum) of terminal males at 2150 mg/kg/day and females at 2400/300 mg/kg/day. 201. 201. 201. id="p-201" id="p-201" id="p-201" id="p-201" id="p-201" id="p-201" id="p-201"
id="p-201"
[000201] In the thymus, lymphoid depletion in the cortex or throughout the tissue was noted.
Though thymic lymphoid depletion is often considered a secondary/stress-related change, the severity of the thymic lymphoid depletion noted in females administered doses 2150 mg/kg/day was considered adverse. The incidence and severity of the microscopic thymic changes are summarized in TABLE 11 below.
TABLE 11 Test Article—related Microscopic Observations Thymus — Terminal Number with Observation Dose level (mg/kg/day) 50 150 400/300 Sex F Number Examined 3 -mild -moderate 31 WO 2021/067549 PCT/US2020/053726 202. 202. 202. id="p-202" id="p-202" id="p-202" id="p-202" id="p-202" id="p-202" id="p-202"
id="p-202"
[000202] In the liver, the hepatocellular hypertrophy associated with the liver weight increases noted was considered an adaptive response and non-adverse (TABLE 12).
TABLE 12 Test Article-related Microscopic Observations Liver — Terminal Number with Observation Dose level: mg/kg/day 0 50 150 400/300 Sex M F M F M F M F Number Examined 3 3 3 3 3 3 4 3 Liver Hypertrophy, hepatocellular, panlobular 0 0 0 3 3 3 3 3 —minimal 0 0 0 0 0 1 0 0 -mild 0 0 O 3 3 2 3 3 [0O0203] Bone marrow depletion noted in males at doses 2150 mg/kg/day and in high—dose animals was considered adverse. The incidence and severity of this microscopic observation is summarized in TABLE 13 below.
TABLE 13 Test Article-related Microscopic Observations Bone Marrow — Terminal Number with Observation Dose level: mg/kg/day 0 50 150 400/300 Sex M F M F M F M F Number Examined 3 3 3 3 3 3 4 3 Bone marrow, femur Depletion, mixed 0 0 0 0 1 0 2 1 —minimal 0 0 0 O 1 0 0 1 —mild O 0 0 0 0 0 1 0 -moderate 0 0 0 0 0 0 1 0 Bone marrow, rib Depletion, mixed 0 0 0 0 1 0 2 1 —minimal 0 0 0 0 1 0 0 0 -mild 0 0 0 0 0 0 1 1 -moderate 0 0 0 0 0 0 1 0 Bone marrow, sternum Depletion, mixed 0 0 O 0 1 0 2 1 —minimal 0 0 0 0 1 0 0 0 —mild O 0 O 0 0 0 1 1 -moderate O 0 0 0 0 0 1 0 [00O204] Given the bone marrow findings summarized above, complete differentials and myeloid/erythroid (M/E) ratios were performed. In males receiving 400/300 mg/kg/day, a mild increase in the M/E ratio (+59%) relative to controls was observed. These findings were generally attributable to reductions in erythroid cells in the two animals which had available data at this dose level. One 400/300 mg/kg/day male had reduced reticulocytes which is consistent with increased M/E ratio. Another 400/300 mg/kg/day male had a mildly increased M/E ratio without an apparent reduction in reticulocytes. The reason for the disharmony between the hematology data and the bone 32 WO 2021/067549 PCT/US2020/053726 marrow findings is uncertain but may be a reflection of manual hematology differentials (less accurate relative to automated). All of these findings were considered 18-MC-related and reflect altered and/or reduced hematopoietic cell populations in the bone marrow. 205. 205. 205. id="p-205" id="p-205" id="p-205" id="p-205" id="p-205" id="p-205" id="p-205"
id="p-205"
[000205] Systemic exposure to 18-MC was independent of sex. Individual 18-MC plasma concentration—time profiles, Cmax, and AUC values were variable and displayed no consistent differences between males and females on Day 1 and Day 14 (the sex ratios ranged from 0.502 to 1.70). The following discussion is therefore based on data for males and females combined. 206. 206. 206. id="p-206" id="p-206" id="p-206" id="p-206" id="p-206" id="p-206" id="p-206"
id="p-206"
[000206] The variability in mean 18-MC plasma concentrations, as measured by CV%, were similar across dose groups and ranged from 38% to 110% on Day 1 and 36% to 154% on Day 14. Median 18-MC plasma concentrations were quantifiable up to 24 hours post dose for all dose groups on Days 1 and 14 (individual Tlast values ranged from 12 to 24 hours post dose). Median peak 18-MC plasma concentrations were observed by 1 hour post dose for all dose groups on Days 1 and 14 (individual Tmax values ranged from 0 to 12 hours post dose). 207. 207. 207. id="p-207" id="p-207" id="p-207" id="p-207" id="p-207" id="p-207" id="p-207"
id="p-207"
[000207] Following oral gavage administration of 18-MC HCI, Cmax and mean systemic exposure (AUCO-24) values of 18-MC increased with increasing dose. A 1:3:8—fo|d increase in dose resulted in an approximate 1:1.4:2.3- fold increase in Cmax and an approximate 1:2.6:3.9-fold increase in AUCO- 24 on Day 1. On Day 14, a 1:3:6- fold increase in dose resulted in an approximate 1:1.3:2.2-fold increase in Cmax and an approximate 1:2.1:3.6- fold increase in AUCO-24. [00O208] Systemic exposure (AUCO-24) generally appeared to decrease following repeated administration of 18-MC HCI. Accumulation ratios could not be determined for the high dose group due the change in dose from 400 to 300 mg/kg following the Day 1 administration. Individual accumulation ratios ranged from 0.297 to 0.866 for the 50 mg/kg dose group with the exception of two females with R values of 1.12 and 2.94, respectively, and ranged from 0.254 to 0.939 for the 150 mg/kg dose group. 209. 209. 209. id="p-209" id="p-209" id="p-209" id="p-209" id="p-209" id="p-209" id="p-209"
id="p-209"
[000209] Mean accumulation ratios were 0.912 and 0.596 for the 50 and 150 mg/kg dose groups, respectively. [00O210] In conclusion: 211. 211. 211. id="p-211" id="p-211" id="p-211" id="p-211" id="p-211" id="p-211" id="p-211"
id="p-211"
[000211] Systemic exposure to 18-MC was independent of sex. Individual 18-MC plasma concentration—time profiles, Cmax, and AUC values were variable and displayed no consistent differences between males and females on Day 1 and Day 14. [0O0212] Following oral gavage administration of 18-MC HCI, mean systemic exposure (AUCO-24) values of 18-MC increased with increasing dose in an approximate dose proportional manner from the low to mid—dose group on Day 1, and in a less than dose proportional manner across the close range on Days 1 and 14. 33 WO 2021/067549 PCT/US2020/053726 213. 213. 213. id="p-213" id="p-213" id="p-213" id="p-213" id="p-213" id="p-213" id="p-213"
id="p-213"
[000213] Following oral gavage administration of 18-MC HCI, mean systemic exposure Cmax values of 18-MC increased with increasing dose in a less than dose proportional manner across the dose range on Days 1 and 14. 214. 214. 214. id="p-214" id="p-214" id="p-214" id="p-214" id="p-214" id="p-214" id="p-214"
id="p-214"
[000214] Systemic exposure (AUCO-24) generally appeared to decrease following repeated administration. 215. 215. 215. id="p-215" id="p-215" id="p-215" id="p-215" id="p-215" id="p-215" id="p-215"
id="p-215"
[000215] Following 14 days of oral 18-MC administration to male and female monkeys (and in the absence of forthcoming recovery/reversibility data), the NOAEL was 50 mg/kg/day, the low dose level of the study. On Day 14, 18-MC plasma AUCo.24 and Cmax values at 400 mg/kg for 1 day followed by 300 mg/kg/day (the NOAEL dose) for t 13 days were 144 ugxhr/mL and 1210 pg/mL, respectively, averaged across the sexes. 216. 216. 216. id="p-216" id="p-216" id="p-216" id="p-216" id="p-216" id="p-216" id="p-216"
id="p-216"
[000216] Genetic Toxicity [00O217] Four GLP studies were performed to assess the genotoxic potential of 18-MC HCI. These tests consisted of two in vitro tests including bacterial mutagenicity (Ames test) and mammalian clastogenicity (chromosome aberration in cells) studies. Two in vivo GLP studies were also conducted. A GLP in vivo micronucleus test with mouse bone marrow and a GLP comet assay study evaluating genetic damage in the liver of mice following oral dosing using single cell gel electrophoresis. In each assay, 18-MC HCI was tested in the absence and presence of metabolic activation (Aroc|or—induced rat liver 8-9). All in vivo assays employed maximum tolerated doses.
Preliminary screening Ames and in vivo micronucleus assays were also conducted and the results consistent with those reported in the definitive studies. 218. 218. 218. id="p-218" id="p-218" id="p-218" id="p-218" id="p-218" id="p-218" id="p-218"
id="p-218"
[000218] Bacterial Reverse Mutation Assay 219. 219. 219. id="p-219" id="p-219" id="p-219" id="p-219" id="p-219" id="p-219" id="p-219"
id="p-219"
[000219] A preliminary non-GLP study evaluated the in vitro mutagenicity of 18-MC HCI in the Ames test. The tester strains used were Salmonella typhimurium histidlne auxotrophs TA98, TA100, TA1535, and TA1537 and Escherichia coli WP2 uvrA. The test article was tested at concentrations of up to 5000 uglplate, along with appropriate vehicle control and positive controls. 18-MC HCI did not cause mutagenic response in any of the tester strains in either the absence or the presence of Aroclor-induced rat liver 89. The test article precipitated at the top 2 concentrations 220. 220. 220. id="p-220" id="p-220" id="p-220" id="p-220" id="p-220" id="p-220" id="p-220"
id="p-220"
[000220] In the GLP study, 18-MC HCI was further evaluated for mutagenic activity in the in vifro Salmone/la—E. coli/mammalian microsome reverse mutation assay using the plate incorporation method. Four tester strains of Salmonella typhimurium (TA1537, TA98, TA100, and TA1535) and one Escherichia coli strain (WP2 uvrA) were used. 18-MC HCI was prepared as a formulation in dimethylsulfoxide (DMSO) and tested at concentrations of up to 500 pg/plate. Mutagenicity testing was performed in triplicate at each concentration with and without an AROCLORT"'1254—induced rat liver S9 metabolic activation system. 34 WO 2021/067549 PCT/US2020/053726 221. 221. 221. id="p-221" id="p-221" id="p-221" id="p-221" id="p-221" id="p-221" id="p-221"
id="p-221"
[000221] Criteria for a negative response were met for all tester strains, with and without metabolic activation. Mean number of revertant colonies following incubation with 18-MC HCI was comparable to historical control ranges at all concentrations for all tester strains with and without metabolic activation. The data from the vehicle and positive controls demonstrated the validity and sensitivity of this test system for detecting chemical mutagens with and without metabolic activation. 222. 222. 222. id="p-222" id="p-222" id="p-222" id="p-222" id="p-222" id="p-222" id="p-222"
id="p-222"
[000222] These data support the conclusion that 18-MC HCI is negative for mutagenic activity in the Salmonella strains TA1537, TA98, TA100, and TA1535 and in the E. coli strain WP2 uvrA, with and without metabolic activation. 223. 223. 223. id="p-223" id="p-223" id="p-223" id="p-223" id="p-223" id="p-223" id="p-223"
id="p-223"
[000223] In Vitro Chromosome Aberration Test in Cultured Human Peripheral Blood Lymphocytes [0OO224] In a GLP study, 18-MC HCI was evaluated for the potential to induce chromosome aberrations in human peripheral blood lymphocytes (HPBL) during short (3-hour) and long (22-hour) incubations with or without an exogenous metabolic activation system. 225. 225. 225. id="p-225" id="p-225" id="p-225" id="p-225" id="p-225" id="p-225" id="p-225"
id="p-225"
[000225] 18-MC HCI was formulated in DMSO and tested in the range-finding assay up to approximately 1 mM, the highest concentration recommended per current regulatory guidance. HPBL cultures were treated with the test article, positive control or vehicle control in the presence and absence of an Aroc|orT'V' 1254-induced rat liver S9 microsomal fraction. Precipitates were observed at the end of treatment at 246.3 ug/mL (0.11 mM) in the 22-hour treatment without metabolic activation and at 292.5 ug/mL (0.22 mM) in the 3-hour treatments with and without metabolic activation. Based on precipitates observed in the range-finding assay, concentrations used during the definitive chromosome aberration assay were a) 7.5, 15, 25, 50, 100, and 150 ug/mL in the 3-hour treatments with and without metabolic activation, and b) 1.0, 15, 25, 30, 35, 40, 45, 50, 55, 60, and 75 ug/mL in the 22-hour treatment without metabolic activation. These cultures along with the vehicle and one concentration of positive control for each treatment condition were analyzed for aberrations.
Structural chromosome aberrations were scored for each concentration from a total of 200 metaphase cells (when possible) or 230 aberrant cells. Numerical aberrations were evaluated in 400 metaphase cells per concentration. 226. 226. 226. id="p-226" id="p-226" id="p-226" id="p-226" id="p-226" id="p-226" id="p-226"
id="p-226"
[000226] A statistically significant increase (p $0.01) in the percent of cells with structural chromosome aberrations was observed in the 3-hour treatment with metabolic activation at 50 and 100 ug/mL (or 123 and 247 (M). Additionally, a statistically significant increase (0 $0.01) in the percent of cells with greater than one aberration was observed in the 3-hour treatment with metabolic activation at 100 pg/mL (246 uM). No statistically significant differences in the percent of cells with structural chromosome aberrations or the percent of cells with greater than one aberration were noted in either the 3- or 22-hour treatments without metabolic activation. There was no statistically significant test article-related increase in numerical aberrations (polyploidy or endoreduplication) in WO 2021/067549 PCT/US2020/053726 any treatment compared to the vehicle controls. The aberrations in vehicle and positive control cultures were comparable to acceptable historical control ranges. 227. 227. 227. id="p-227" id="p-227" id="p-227" id="p-227" id="p-227" id="p-227" id="p-227"
id="p-227"
[000227] Based upon the results of this assay, 18-MC HCI was considered positive for inducting structural aberrations in HPBL with metabolic activation and negative for inducing structural aberrations in HPBL without metabolic activation under the conditions of this test system. These in vitro results were not corroborated in mice following oral administration. No evidence of clastogenicity or genotoxicity was observed in the in vivo micronucleus assay or the in vivo comet test. 228. 228. 228. id="p-228" id="p-228" id="p-228" id="p-228" id="p-228" id="p-228" id="p-228"
id="p-228"
[000228] Mouse Bone Marrow In Vivo Micronucleus Assav [0OO229] The potential of 18-MC to induce micronuclei in polychromatic erythrocytes in mouse bone marrow in order to assess its potential in vivo clastogenic activity and/or to disrupt the mitotic apparatus. [00O230] Initially, a non-GLP screening study evaluated the toxicity and genotoxicity of 18-MC in ICR mice following a single oral administration of 18-MC HCI at dose levels of 100, 150, 200, 250, 300 and 400 mg/kg formulated in phosphate buffered saline, pH 7.4, as a suspension (not the formulation utilized for GLP studies). Treatment resulted and clinical signs of lethargy and piloerection at doses of 200-400 mg/kg and in mortality of male and female ICR mice at doses of 300 and 400 mg/kg. The highest non—lethal dose was 250 mg/kg. No significant increase in the incidence of micro- nucleated polychromatic erythrocytes (MPCE) in bone marrow of male and female ICR mice at dose levels without mortality (250 mg/kg and less) was observed compared to vehicle control groups. 231. 231. 231. id="p-231" id="p-231" id="p-231" id="p-231" id="p-231" id="p-231" id="p-231"
id="p-231"
[000231] In the definitive GLP study, 18-MC HCI was formulated in the vehicle (5% dextrose, pH=3) and administered orally by gavage once daily for 3 consecutive days to male Crl:CD1(lCR) mice at dosage levels of 50, 75, and 120 mg/kg/day. These doses were based upon prior toxicology data indicating higher doses were associated with mortality in this species. A concurrent vehicle control group received the vehicle on a comparable regimen. A positive control group received a single oral dose of 60 mg/kg cyclophosphamide on Day 2, the day prior to the scheduled euthanasia.
Each group consisted of 6 males. Males only were used as no significant differences in response related to gender were expected based upon prior toxicology and toxicokinetic data. All animals were euthanized on Day 3, the day following the final close and discarded following bone marrow collection. 232. 232. 232. id="p-232" id="p-232" id="p-232" id="p-232" id="p-232" id="p-232" id="p-232"
id="p-232"
[000232] All animals were observed twice daily for mortality and moribundity. Bone marrow collection for micronucleus evaluation was performed for 5 of the 6 animals in each group at the scheduled euthanasia (Day 3). All animals were discarded without necropsy. Bone marrow smears were prepared, and the coded slides were counted for polychromatic, normochromatic, and micronucleated polychromatic erythrocytes following the final bone marrow sample collection on Day 3. 36 WO 2021/067549 PCT/US2020/053726 233. 233. 233. id="p-233" id="p-233" id="p-233" id="p-233" id="p-233" id="p-233" id="p-233"
id="p-233"
[000233] Lethality was observed in a single animal in the 120 mg/kg/day group within 3 hours of dosing. There were no remarkable clinical or macroscopic findings noted in this animal at necropsy.
Given that a low frequency in mortality within 3 hours of dosing had been seen at this dose in prior studies, the death was considered test article-related. All other animals survived until the scheduled euthanasia. 234. 234. 234. id="p-234" id="p-234" id="p-234" id="p-234" id="p-234" id="p-234" id="p-234"
id="p-234"
[000234] There were no test artic|e—re|ated effects on clinical observations, body weights, or food consumption. 235. 235. 235. id="p-235" id="p-235" id="p-235" id="p-235" id="p-235" id="p-235" id="p-235"
id="p-235"
[000235] The test article did not produce an increase in the percent mean number of micronucleated polychromatic erythrocytes (%MN-PCEs) compared to the vehicle control. No bone marrow cytotoxicity (decreases in the ratio of polychromatic to total erythrocytes, PCE:TE ratio) was noted in any test article-treated group. Vehicle and positive control values were within the expected historic ranges validating the study results. Therefore, 18-MC met the criteria for a negative response for bone marrow cytotoxicity and clastogenic activity and/or disruption of the mitotic apparatus under the conditions of this assay. 236. 236. 236. id="p-236" id="p-236" id="p-236" id="p-236" id="p-236" id="p-236" id="p-236"
id="p-236"
[000236] In l/ivo Comet Assay 237. 237. 237. id="p-237" id="p-237" id="p-237" id="p-237" id="p-237" id="p-237" id="p-237"
id="p-237"
[000237] The genotoxic potential of 18-MC HCI was evaluated for its ability to induce DNA damage in mouse liver using the principles of comet assay. The comet assay (alkaline single cell gel electrophoresis) is a microgel electrophoretic technique that detects DNA damage in individual cells.
DNA damage can be expressed as DNA single strand breaks, double strand breaks, and strand breaks induced by alkali labile sites. This study was initiated on the basis of results of the in vitro chromosomal aberration assay that indicated a positive response with 18-MC HCI in the presence of metabolic activation. For this study, the liver was selected as the tissue for evaluation, since this tissue is expected to contain high concentrations of parent drug and metabolites following oral administration. 238. 238. 238. id="p-238" id="p-238" id="p-238" id="p-238" id="p-238" id="p-238" id="p-238"
id="p-238"
[000238] Male mice were administered oral doses of 0 (vehicle=5% dextrose), 50, 90 and 120 mg/kg/day by gavage according to the table below. Animals in groups 1-4 were dosed on three consecutive days and euthanized 3 to 4 hours after the last dose by C02 inhalation. A separate group of animals were dosed with methyl methanesulfonate (MMS) which served as a positive control.
Immediately following euthanasia, the liver was removed and collected from each animal. 239. 239. 239. id="p-239" id="p-239" id="p-239" id="p-239" id="p-239" id="p-239" id="p-239"
id="p-239"
[000239] In this study, comet tail migration, % tail DNA (also known as % tail intensity) and tail moment were determined for each animal/treatment group and served as parameters of DNA damage. Though a statistically significant increase mean °/o tail DNA relative to the vehicle control was observed at a dose of 90 mg/kg/day (2.60 +/— 0.7 vs. 1.27 +/— 0.52), a similar increase was not seen in the high-dose group and the 90 mg/kg group mean value was well within the upper bound of 37 WO 2021/067549 PCT/US2020/053726 the historical control range (mean -4.42). The positive control (MMS) produced the expected increases in comet parameters validating the results of the assay. 240. 240. 240. id="p-240" id="p-240" id="p-240" id="p-240" id="p-240" id="p-240" id="p-240"
id="p-240"
[000240] Based upon the results of this study, 18-MC HCI is considered negative in the mouse comet assay. These results are consistent with prior in vivo micronucleus studies and collectively suggest 18-MC HCI does not pose significant genotoxic risk. 241. 241. 241. id="p-241" id="p-241" id="p-241" id="p-241" id="p-241" id="p-241" id="p-241"
id="p-241"
[000241] EXAMPLE 6 [00O242] Clinical Study [0O0243] Fourteen normal, healthy volunteers were enrolled in the study. Seven volunteers were treated in the first cohort (3 placebo, 4 received a single dose of 20 mg of 18-MC) and seven in the second cohort (2 placebo, 5 received 8 mg as 4 mg doses of 18-MC administered at O and plus 10 hours). For Cohort A, volunteers were monitored in a hospital unit for 2 days (36 hours) days, and were followed up for safety at Days 3, 7 and 30. For Cohort B, volunteers were monitored in a hospital unit for 2 days (36 hours), and were followed up for safety at Days 3, 4, 7 and 30.
[O0O244] Study objectives: To determine the safety and tolerability of the drug 18-MC, and to evaluate the biochemical (safety) parameters of the individual participants and to determine pharmacokinetic (PK) parameters. 245. 245. 245. id="p-245" id="p-245" id="p-245" id="p-245" id="p-245" id="p-245" id="p-245"
id="p-245"
[000245] Study Design [00O246] This study was designed as a randomized, double-blind, placebo-controlled, single-center Phase 1 first-in-human clinical trial. After screening, volunteers were admitted to the hospital for 36 hours. On the first day of dosing, a sentinel group of one active and one placebo were treated to evaluate any significant safety signal, the remaining volunteers were enrolled after the successful sentinel group. Study article was initiated on Day 1 and volunteers were discharged on Day 2. Cohort A were seen as outpatients on Days 3, 7 and 30. Cohort B were seen as outpatients on Days 3, 4, 7 and 30. 14 subjects were in the study, 5 male and 9 female. None discontinued the study. 247. 247. 247. id="p-247" id="p-247" id="p-247" id="p-247" id="p-247" id="p-247" id="p-247"
id="p-247"
[000247] The study plan as stated in the protocol was to include two cohorts treated as single dose treatment groups, the first to receive 20 mg of 18-MC or placebo (4 and 3 volunteers, respectively) and the second to receive 60 mg 18-MC or placebo (also 4 and 3, respectively). This was to be followed by a multi—dose protocol part with two cohorts. The subjects were to be administered three daily doses of 20 mg (5 active and 3 placebo) followed by another cohort with the subjects receiving 60 mg 18-MC (also 5 active and 3 placebo). An expansion of the multi—dose part was also planned, but neither the second single dose cohort nor the multi—dose treatment groups were conducted due to unexpectedly high plasma levels in the single dose treatment group. 248. 248. 248. id="p-248" id="p-248" id="p-248" id="p-248" id="p-248" id="p-248" id="p-248"
id="p-248"
[000248] The 20 mg treatment group of stage 1A returned plasma concentrations more than 20- fold higher than had been anticipated based upon nonclinical study results. As a result, an 38 WO 2021/067549 PCT/US2020/053726 amendment (#2) to the protocol was filed and, instead of the planned 60 mg treatment group, seven volunteers were enrolled in a lower dose treatment group of 8 mg 18-MC or placebo (5 active and 2 placebo volunteers, respectively) administered as 4 mg in the morning and repeated 10 hours later was enrolled. TABLE 14 shows the dosage/formulation numbers: TABLE 14 Product Name and Potency Dosage Form Formulation No./Lot No. 18-MC Drug API in 5% dextrose/Normal Saline C001 (Cohort A) 090ct2014 (Cohort B) Placebo 5% dextrose/Normal Saline C002 (Cohort A) 090ct2014 (Cohort B) 249. 249. 249. id="p-249" id="p-249" id="p-249" id="p-249" id="p-249" id="p-249" id="p-249"
id="p-249"
[000249] Major inclusion criteria include: Men and/or non-pregnant women 18 years to a maximum of 40 years of age; subjects must be able to read, understand and sign the Statement of Consent; subjects must not be a carrier of any chronic disease that requires continuous use of any drug; and subjects must be in good physical and mental health, based on medical history, physical examination and laboratory results assessed during the selection process of volunteers. [00O250] Major exclusion criteria include: Abnormal biochemical parameters of blood and urine; history of major organ dysfunction, including but not limited to liver disease, heart disease, kidney disease; history of hypertension or hypertension; cancer or history of cancer; presence of any psychological abnormality at the discretion of the investigators, might interfere with the study; diabetes; any clinically important infectious disease, including but not limited to AIDS and hepatitis; substance abuse of tobacco or any other type of drug that can act in the CNS; and pregnancy. 251. 251. 251. id="p-251" id="p-251" id="p-251" id="p-251" id="p-251" id="p-251" id="p-251"
id="p-251"
[000251] Evaluation criteria [00O252] All volunteers must sign the Statement of Informed Consent before any study procedures, including screening tests, are performed. [0O0253] Determination of medical history is performed, including the evaluation of all inclusion and exclusion criteria, demographic data (age, sex, race, menstrual status, weight, height), history of present illness, history of hypersensitivity (allergy medications), history and general medical evaluation of all data including the current severity of symptoms. [0O0254] A review of medication was performed, detailed physical examination was performed, adverse events were evaluated and graded. [0O0255] Clinical laboratory: Hematology was performed: complete blood count (CBC), differential, platelet count, PT, PTT Serum chemistry: albumin, total protein, bilirubin, lactate dehydrogenase (LDH), ALT / AST, AST / ALT, creatinine, urea nitrogen (BUN), glucose and electrolytes, cholesterol and HDL-C and LDL-C, triglycerides, LH , FSH, prolactin, TSH, T3, T4. Urinalysis was performed: Sediment, culture, colony counts and antibiotic, if necessary. A pregnancy test was performed (serum 39 or urine, females only). ECG and EEG were performed. 256. 256. 256. id="p-256" id="p-256" id="p-256" id="p-256" id="p-256" id="p-256" id="p-256"
id="p-256"
[000256] Results 257. 257. 257. id="p-257" id="p-257" id="p-257" id="p-257" id="p-257" id="p-257" id="p-257"
id="p-257"
[000257] Pharmacokinetics 258. 258. 258. id="p-258" id="p-258" id="p-258" id="p-258" id="p-258" id="p-258" id="p-258"
id="p-258"
[000258] 6.0, 12.0, 24, 36 hours, and 7 days post dose. For Cohort B, the collection times were modified to account for the elimination phase rate constant and the ha|f—|ife to the following times: baseline and 0.25, 0.5, 1.0, 2.0, 6.0, 9.5, 10.25, 11, 12, 16, 22, 35 72, 96 and 168 hours, and 7 days post initial dose (a second dose was administered 10 hours after the initial dose). Results are summarized in TABLE 15 for cohort A and TABLE 16 for cohort B.
TABLE 15 Summary pharmacokinetic parameters of 18—MC, M2, M4 and M5 based on individual subjects’ parameters, cohort A (20 mg PO single dose) Half-Life Tmax Cmax AUCa|| AUCin1 Analyte (hr) (hr) (ng/mL) (hr*ng/mL) (hg*fl/mL) 18—MC Average 17.9 0.5 119 339 397 Min 14.2 0.5 92 241 261 Max 21.7 0.5 182 447 531 M2 Average 14.4 1.4 41 563 678 Min 11.1 0.5 27 504 627 Max 19.0 2.0 62 684 765 M4 Average 7.9 1.4 347 2692 2799 Min 6.3 0.5 242 1897 1978 Max 9.3 2.0 528 3925 4058 M5 Average 29.6 0.8 25 210 395 Min 16.2 0.5 12 105 195 Max 43.4 1.0 38 359 735 TABLE 16 Summary pharmacokinetic parameters of 18—MC, M2, M4 and M5 based on the individual subjects’ parameters, cohort B (4 mg PO at 0 and + 10 hours) Half-Life Tmax Cmax AUCa|| AUCinf Analyte (hr) (hr) (ng/mL) (hr*ng/mL) (hg*fl/mL) 18—MC Average 16.9 2.55 30 195 199 Min 3.0 0.5 20 124 117 Max 52.2 10.25 46 400 430 M2 Average 44.1 11.8 11 391 420 Min 18.7 11 8 287 283 Max 97.8 12 12 500 570 M4 Average 22.1 7.3 72.3 1648 Min 13.2 0.5 65 1304 Max 34.3 12 82 1941 M5 Average 46.8 2.9 6 163 Min 19.8 0.5 3 104 Max 74.7 1 1 9 208 40 For Cohort A, pharmacokinetic samples were obtained at baseline and at 0.5, 1.0, 2.0, 1 654 1296 1 975 185 145 233 WO 2021/067549 PCT/US2020/053726 [00O259] Samples underwent two analyses: A research assay (LC/MS/TOF) developed by MicroConstants, Inc was used to collect the raw data. The first analysis was to quantitate 18-MC and the known metabolites M2, M4 and M5 (using standard curves included in the run). The second analysis compared the peak heights of 18-MC and all the metabolites that could be identified in terms of relative peak height (M1 through M10, and P1 — P3). As the core structure of all of the metabolites is similar, it is very likely that the absorption and ionization is similar to those of the parent. Structures are shown for the metabolites in FIGURES 21A-21 J. 260. 260. 260. id="p-260" id="p-260" id="p-260" id="p-260" id="p-260" id="p-260" id="p-260"
id="p-260"
[000260] After the administration of 18-MC in either cohort A or B the plasma concentrations of 18- MC, M2, M4 and M5 appeared quickly. The Tmax for 18-MC, M4 and M5 occurred generally within 1/2 hour and the Tmax was possibly slightly delayed for M2. After the administration of 20 mg in cohort A, the Cmax of 18-MC was 119 ng/mL while M4 Cmax mean concentration is about 2.5 fold higher (347 ng/mL), and the Cmax of M2 and M5 was slightly lower than the Cmax of 18-MC. After the 8 mg dose administered as 4 mg at 0 and + 10 hours in cohort B, the Cmax of 18-MC was about 30 ng/mL, and the Cmax of M4 was 72 ng/mL. The exposure (AUCa||) after the 20 mg dose of 18-MC was 339 hrs.*ng/L while the exposure of M4 was 2692 hr*ng/mL. The exposures of M2 and M5 were slightly lower than 18-MC. After the second administration of the 4 mg dose (total of 8 mg) the exposure of 18-MC (AUCa||) was 195 hr*ng/mL while that of M4 was 1648 hr*ng/mL. The pharmacokinetics appeared to follow a multiple—compartment model (see FIGURE 17). After the 20 mg dose, the sampling interval was short compared to the elimination half-life, so the data should be considered preliminary. After the 4 mg at 0 and +10 hours (8 mg total), with the longer sampling interval the elimination half-life of 18-MC and the metabolites was about 48 hours. Comparing the 8 mg dose of 4 mg given twice to the single 20 mg dose, the Cmax after the 20 mg dose increased proportionally compared to the initial 4 mg dose while the exposure (AUC) increased slightly less then proportionally (2-fold versus an increase in dose of 2.5-fold). 261. 261. 261. id="p-261" id="p-261" id="p-261" id="p-261" id="p-261" id="p-261" id="p-261"
id="p-261"
[000261] The relative concentrations of the metabolites were determined using peak—heights, with 16 different metabolites identified. Based on exposure of total drug-related substance (calculated as the sum of the AUCs from all of the metabolites plus 18-MC), 18-MC was only a very minor amount of the circulating drug-related material (ranging from 4 to 9 percent). After the 20 mg single dose, M4 was the only major metabolite while M8 was borderline (percentage of the exposure between 8 and %). After the administration of 4 mg twice at 0 and +10 hours (total 8 mg), the relative major metabolites changed. Only two metabolites were present at greater than 10% of the total drug related material; M4 (about 40%) and P10, while the exposure of M8 was less than 10% of the total drug related material. P10 accumulated very late (Tmax ranging from 6 to 10 hours) with a very long 41 WO 2021/067549 PCT/US2020/053726 elimination half-life that did not allow for appropriate estimation (probably many days) of the elimination rate constant and half-life. As P10 appears as a major metabolite and the elimination could not be adequately determined, the total drug related exposure (to infinity) was not adequately characterized. 262. 262. 262. id="p-262" id="p-262" id="p-262" id="p-262" id="p-262" id="p-262" id="p-262"
id="p-262"
[000262] Ly 263. 263. 263. id="p-263" id="p-263" id="p-263" id="p-263" id="p-263" id="p-263" id="p-263"
id="p-263"
[000263] Safety was monitored by reported adverse events, hematology, serum chemistries (including electrolytes, renal and liver function, urinalysis, ECG and vital signs. In addition, a neurological examination (mini-mental status exam) including assessment for abnormal eye movement, nystagmus, tremors, reflexes, upper and lower extremity strength, distal sensor perception, intention tremor, the Romberg test, excessive somnolence and mental status were performed. [00O264] Adverse Events [00O265] No serious adverse events occurred. The following TABLE 17 summarizes the reported adverse events: TABLE 17 Active Subject AE Description Day Noted Severity Study Drug related‘ A1 Nausea 1 1 2 A1 Arterial Hypotension 1 1 2 A1 Pain — submandibular lymph node 1 1 2 A1 Urinary tract infection 2-30 2 1 A2 Retro-orbital headache — right after medication, 1 1 2 during about 15 minutes (patient said it after hearing the other patient report the same event.) A3 Hot coffee burn in hand and right forearm 7 1 1 A4 Dry cough (1 1 minute after 18MC administration 4 1 3 / lasted about 10 minutes) in the two administrations* A5 Body pain 30 1 1 A6 Occipital and frontal headache (lasted 1 3 hours) 4 2 1 * CRF entry error. No drug was dosed on day 4.
Placebo AE Description Day Severity Study Drug related‘ Subject Noted P1 Retro-orbital headache — right after medication, 1 1 2 during about 15 minutes (patient said it after hearing the other patient report the same event.) P1 Sore throat 1 1 1 P2 Dry cough (at 07:00h, lasting i 05 minutes) 3 1 1 P2 Flu 4 1 1 P3 Occipital headache 2 2 2 (started at: i 20:30h / lasted: 2 hours) P3 Sensation of "shock" in the left hand when 7 1 1 moved, right above of the index finger, where the venous catheter was used P3 Bloated feeling 30 1 1 P3 Sensation of shock and pain in the left hand 30 1 1 266. 266. 266. id="p-266" id="p-266" id="p-266" id="p-266" id="p-266" id="p-266" id="p-266"
id="p-266"
[000266] 2 STUDY DRUG RELATED 42 WO 2021/067549 PCT/US2020/053726 267. 267. 267. id="p-267" id="p-267" id="p-267" id="p-267" id="p-267" id="p-267" id="p-267"
id="p-267"
[000267] 1 Not related, 2 Possible, 3 Probable. 268. 268. 268. id="p-268" id="p-268" id="p-268" id="p-268" id="p-268" id="p-268" id="p-268"
id="p-268"
[000268] Clinical Observations 269. 269. 269. id="p-269" id="p-269" id="p-269" id="p-269" id="p-269" id="p-269" id="p-269"
id="p-269"
[000269] No clinically significant laboratory abnormalities were noted in any volunteer. The Principal Investigator evaluated each result outside of the laboratories normal range and determined they were ‘not clinically significant (NCS)’. 270. 270. 270. id="p-270" id="p-270" id="p-270" id="p-270" id="p-270" id="p-270" id="p-270"
id="p-270"
[000270] No clinically significant abnormalities on electrocardiograms (ECGs) were noted on the Case Report Forms by the clinical investigators. One Subject in cohort A presented with a disturbance in right bundle branch conduction on Day 30 that was determined not to be of clinical significance. 271. 271. 271. id="p-271" id="p-271" id="p-271" id="p-271" id="p-271" id="p-271" id="p-271"
id="p-271"
[000271] No clinically significant abnormalities on electroencephalographs (EEGs) were noted on the Case Report Forms. [00O272] No clinically significant abnormalities occurred on neurological examination were noted on the Case Report Forms. 273. 273. 273. id="p-273" id="p-273" id="p-273" id="p-273" id="p-273" id="p-273" id="p-273"
id="p-273"
[000273] Case Reports 274. 274. 274. id="p-274" id="p-274" id="p-274" id="p-274" id="p-274" id="p-274" id="p-274"
id="p-274"
[000274] Subject 004A1 is a 26 year old healthy small female who entered the study on 7/3/14 in cohort A for screening. Her weight is 45.8 Kg and height 159 cm with a BMI of 18.2. Vital signs on screening were normal (BP 110/70, Temp 37.2, RR 20, and HR 103), although HR was a little high at 103. Physical exam and screening laboratories were normal although Hb was borderline normal at 12.9. ECG and mental status examination were unremarkable. The subject began study treatment on 7/9/14 and vital signs prior to dosing were normal as was the HR at 76 (BP 120/80, RR 20, temp 36.8, HR 76). Her Hb at this time was slightly abnormal at 12.4 (but not deemed clinically significant in a young healthy female). At 08:28 the subject received a single dose of 20 mg 18-MC as per protocol. By 08:58 (30 minutes post dosing), the subject was experiencing nausea and her blood pressure measured 80/60. The subject was treated symptomatically and within 15 minutes the blood pressure returned to normal and nausea resolved within 30 minutes. 275. 275. 275. id="p-275" id="p-275" id="p-275" id="p-275" id="p-275" id="p-275" id="p-275"
id="p-275"
[000275] Both AE’s were rated as grade 1 and possibly related. Blood tests at this time (30 minutes post dosing) showed normal chemistry (Na 141.3, K 4.2 and Cl 107) and Hb slightly below normal range at 12.2. Blood was drawn 30 minutes later (1 hour post dosing) and showed normal Na (145) and K (3.6) with an abnormal Cl (114) and Hb 11.6. Next blood draw at 2 hours post dosing showed normal K and slightly elevated Na (147.5) and Cl (115) and Hb (11.9). At 6 hours post dosing, subject’s laboratories showed a borderline high Na (145), and Cl (121) and a lower than normal Ca (7.2) and total protein (5.25) with a Hb 12.0. At 12 hours her electrolytes were normal except for a slightly elevated Cl (113) and an elevated glucose (114) with a Hb 11.9. By 24 hours, the subject’s blood chemistries were normal except for a slightly elevated Cl (111). Hb was normal at 12.7. 43 WO 2021/067549 PCT/US2020/053726 However, the subject had 8 leukocytes in her urine. The subject was monitored in the Clinical Unit for another 12 hours, and prior to discharge all chemistries and hematology were normal except for urinalysis which had >50 leukocytes. This was classified as a grade 2 AE (urinary tract infection) of possible relationship. All other examinations (VS, ECG, mental status exam) during the 36 hours were unremarkable. This subject (as were the other subjects in the cohort) were followed for 30 days post treatment and there were no further adverse events. [00O276] Plasma 18-MC levels and metabolites were measured, and although the subject was at the lower limits of BMI (18.2), PK analysis demonstrated that 18-MC and its major metabolite M4 were in the mean average range for the group of 4 subjects treated in Cohort A (20 mg 18-MC single dose). However, it should be noted that the 20 mg single dose generated plasma 18-MC levels that were much higher than expected based on pre-clinical toxicology studies. 277. 277. 277. id="p-277" id="p-277" id="p-277" id="p-277" id="p-277" id="p-277" id="p-277"
id="p-277"
[000277] In summary, Subject O04A1 received a 20 mg single dose of 18-MC and experienced a hypotensive event with nausea about 30 minutes post dosing. The subject was treated symptomatically and recovered within 15-30 minutes. Post event there were some electrolyte abnormalities most notably Cl and a slight decrease in Hb to below normal levels which lasted about 12 hours. At 24 hours the chemistry and hematology tests were normal but the subject was noted to have leukocytes in her urine and by 36 hours post dosing the subject was diagnosed with a UTI.
These adverse events were possibly related although it cannot be ruled out that all findings could be accounted for by anxiety (note: screening HR=103) in a small female with a borderline low HB and a smoldering UTI. 278. 278. 278. id="p-278" id="p-278" id="p-278" id="p-278" id="p-278" id="p-278" id="p-278"
id="p-278"
[000278] Conclusion 279. 279. 279. id="p-279" id="p-279" id="p-279" id="p-279" id="p-279" id="p-279" id="p-279"
id="p-279"
[000279] This was a first in human study for 18-MC. The starting dose of 20 mg was selected based on regulatory criteria of starting with 1/10"‘ the NOAEL in the most sensitive species; in this case the mouse. Due to unexpected higher plasma levels in the 20 mg single dose cohort, the dose for the second cohort was lowered to 8 mg (4 mg b.i.d.). 18-MC was tolerated in a dose range of 8 mg to 20 mg. TEAE’s that may be study article related were grade 1 and mild in nature for either hypotension or headache. Because 18-MC has a short distribution half-life and longer terminal half- life, the second cohort, cohort 2 was closed twice a day (b.i.d) for a single day. The b.i.d. dose was chosen so that the subjects would have significant exposures throughout the first day [00O280] The PK over the dose range from 4 mg to 20 mg was relatively linear for both Cmax and AUC. Because of the safety assessment and the observation that the PK analysis demonstrated relatively linear PK over the dose of range of 4 mg to 20 mg, it was determined that there was no further scientific/medical need to continue the study for a third cohort dose of 16 mg (8 mg b.i.d.) as would be allowed in amendment #2. 44 WO 2021/067549 PCT/US2020/053726 281. 281. 281. id="p-281" id="p-281" id="p-281" id="p-281" id="p-281" id="p-281" id="p-281"
id="p-281"
[000281] 18-MC was safe when administered in doses up to 20 mg in the healthy volunteers in this FIH study and is appropriate for advancement to a multi-ascending dose clinical trial. 282. 282. 282. id="p-282" id="p-282" id="p-282" id="p-282" id="p-282" id="p-282" id="p-282"
id="p-282"
[000282] EXAMPLE 7 283. 283. 283. id="p-283" id="p-283" id="p-283" id="p-283" id="p-283" id="p-283" id="p-283"
id="p-283"
[000283] STUDY OBJECTIVE 284. 284. 284. id="p-284" id="p-284" id="p-284" id="p-284" id="p-284" id="p-284" id="p-284"
id="p-284"
[000284] The objective of this study was to determine the functional activities of the M4 and M5 metabolites of 18-MC HCI at the rat 0:364 nicotinic acetylcholine receptor (nAChR) and to compare their potencies to the parent compound. Studies were performed in HEK 293 cells expressing rat recombinant receptors, voltage clamped at -70 mV and tested by fast perfusion. [0O0285] Patch-clamp recording 286. 286. 286. id="p-286" id="p-286" id="p-286" id="p-286" id="p-286" id="p-286" id="p-286"
id="p-286"
[000286] Human embryonic kidney 293 fibroblasts (ATCC CRL1573) were cultured in minimum essential medium supplemented with 10% fetal bovine serum and 2 mM glutamine (Life Technologies). Cells were transfected using Lipofectamine 2000 (Life Technologies) with cDNA's for the rat nicotinic a3 and [34 receptor subunits at a 1:1 ratio with enhanced green fluorescent protein (10% of total cDNA, w:w) included as a visual marker for transfected cells. Functional analyses were performed between 16-42 hours post—transfection. Cells were examined by vo|tage—c|amp recording at -70 mV in the whole-cell configuration using an Axopatch 200A patch-clamp amplifier (Axon Instruments). Thin—walled borosilicate glass microelectrodes (TW150F, World Precision Instruments) had resistances of 3-5 M!) when filled with an internal solution containing (in mM): 135 CsC|, 10 CsF, HEPES, 5 EGTA, 1 MgC|2, and 0.5 CaC|2 at pH 7.2. Current responses were filtered at 5 kHz with an 8-pole Bessel filter (Cygnus Technologies), digitized at 1 kHz, and stored on a Macintosh PowerPC-G3 computer using an ITC-16 interface (lnstrutech) under control of the data acquisition and analysis program Synapse (Synergy Research). Cells were continuously superfused with extracellular solution containing (in mM): 150 NaCl, 3 KCI, 5 HEPES, 1 MgC|2, 1.8 CaCl2, 10 glucose, and 0.1 mg/ml phenol red, pH 7.3. Control, agonist, and test article solutions were applied to individual cells by rapid perfusion with a 30 s inter—trial interval. Solutions were driven by a syringe pump through a flowpipe having 6 or 8 inputs that converge at a single common output of approximately 100 um diameter. Rapid switching between inputs was achieved using a set of upstream solenoid valves (Lee Co.) under computer control.
[O0O287] |C50 Determination [00O288] Metabolites (M4 and M5) at concentrations from 1 to 30 uM were tested for inhibition of 1 mM ACh-evoked currents in recombinant d3[34 receptors using methods previously described (Pace et al., 2004). These experiments used an 8-barrel flow pipe to deliver ACh alone or ACh plus varying concentrations of the test metabolite in the same cells in ascending order. The solution exchange protocol delivered a 5 second ACh pulse (1 mM) having 2 second combined application of M4 or M5 45 WO 2021/067549 PCT/US2020/053726 delivered in the middle of the ACh pulse. Recordings of 7-8 cells were collected per concentration.
ACh-evoked current amplitudes were compared across conditions, and |C50 values were determined by fitting the dose-inhibition curves to the current amplitude measures relative to ACh controls; curve fits are given for the logistic equation: I = Imax /(1+[drug]/|C50). Metabolite association and dissociation kinetics were determined by single—exponential fits to the current decays related to the onset of block and recovery from block, respectively, of 1 mM ACh-evoked currents by 30 uM metabolite. 289. 289. 289. id="p-289" id="p-289" id="p-289" id="p-289" id="p-289" id="p-289" id="p-289"
id="p-289"
[000289] Kinetic profiles: The kinetics of block and recovery were recorded at a fixed concentration of 30 uM M4 (1 OX |C50) or M5 metabolite (~ |C35) from data obtained by the |C50 protocol described above. Three complementary assays were performed to test M4 or M5 actions on 1 mM ACh-evoked currents in recombinant oi3B4 receptors: (1) Simultaneous combined application of M4 or M5 with ACh was used to measure the extent of block and the rates of onset of block from the resting state. (2) Combined M4 or M5 with ACh application following pre-exposure to M4 or M5 was used to measure the extent of block and the rates of onset of block from the drug-bound state. (3) ACh application alone following pre-exposure and removal of M4 or M5 was used to measure the intrinsic ACh current decay rate (desensitization) from the drug-bound state and to confirm that M4 or M5 binding can occur in the absence of ACh activation. [00O290] Test article and vehicle formulations 291. 291. 291. id="p-291" id="p-291" id="p-291" id="p-291" id="p-291" id="p-291" id="p-291"
id="p-291"
[000291] 18-MC HCI (lot no. OBI-215-21-3) was obtained from Obiter Research. M4 and M5 were provided by Savant HWP. Solid compounds were stored at -20°C in a drying desiccator. LC-MS analysis of M4 and M5 are provided in the Appendix. Test articles were dissolved in DMSO to prepare 10 mM stocks of 18-MC HCI and 20 mM stocks of M4 and M5. 1 M acetylcholine stocks were made up in extracellular solution. Stocks were stored frozen at —20°C. 292. 292. 292. id="p-292" id="p-292" id="p-292" id="p-292" id="p-292" id="p-292" id="p-292"
id="p-292"
[000292] Perfusion solutions containing ACh, 18-MC HCL, M4 or M5 were prepared freshly by dilution to the appropriate concentrations in extracellular solution containing 150 mM NaCl, 3 mM KCI, mM HEPES, 1 mM MgCl2, 1.8 mM CaC|2, 10 mM glucose, and 0.1 mg/ml phenol red adjusted to pH 7.3 with NaOH. 293. 293. 293. id="p-293" id="p-293" id="p-293" id="p-293" id="p-293" id="p-293" id="p-293"
id="p-293"
[000293] a [O0O294] |C50 Determination 295. 295. 295. id="p-295" id="p-295" id="p-295" id="p-295" id="p-295" id="p-295" id="p-295"
id="p-295"
[000295] Metabolite lC50 values were determined as previously described for 18-MC HCI using a combined application protocol whereby varying metabolite concentrations up to 30 uM were co- applied during 1 mM ACh-evoked currents. Metabolite pulses were 2 sec duration during a 5 sec ACh-evoked response. Example traces are shown in FIGURES 18A, 18C, which illustrate the dose- dependent inhibition of ACh-evoked currents. Using this same protocol, the |C5O for 18-MC HCI was 46 WO 2021/067549 PCT/US2020/053726 previously resolved at 0.75 uM (Pace et al., 2002), which is re-plotted in Figure 18E for reference. In respectively. Note, however, because M5 was very weak, the M5 |C5O value was estimated by extrapolation beyond the highest 30 uM concentration tested. Similar results were seen using combined application for 2 sec without ACh pre-exposure (Figures 18B, 18D). [0O0296] Kinetic parameters [00O297] Using current traces derived from the highest concentrations tested, we estimated several kinetic parameters related to metabolite inhibition. The metabolite results are shown in FIGURES 18A-18E and summarized in[sEp]TABLE 18. The drug association and dissociation rates were derived as follows: kon is given as the reciprocal of the exponential time constant fitting the rate of inhibition (Tb|0Ck); koff is given as the reciprocal of the exponential time constant fitting the rate of recovery from block (trecov). Persistent inhibition at 1 second after removal of drug is an index of the stability of the bound state when koff is too slow to be reliably measured. Of note, both M4 and especially M5 appear to dissociate much faster than 18-MC HCI from the oi3B4 receptors, while M5 also exhibits a considerably slower association rate suggesting that this metabolite introduces an electrostatic or steric incompatibility with binding to the modulator binding site.
Table 18 Kinetic Parameters of 18-MC and Metabolites M4, M5 . . . Persistent Test Compound kon (s-1) koff (s-1) 35:0 '"""f,"'°" Inhibition at 1 ' PM (/°) sec (%) 18-MC HCI 5.5 4_r 0.4 nd 98 :1 88 : 3 M4 4.5 420.4 2.5 :o.4 as :3 21 :3 M5 2.2 : 0.4 6.2 : 0.2 36 : 5* 2 : 2* [OOO298] M4 and M5 = 30 pM; 18-MC HCI = 20 uM (from Kuehne et al., 2003); nd= not determined because the rate of recovery was too slow to fit. *Maximum inhibition and persistent inhibition at 1 sec for M5 were measured at 30 pM which was a non-saturating concentration less than 10X of its |C50. 299. 299. 299. id="p-299" id="p-299" id="p-299" id="p-299" id="p-299" id="p-299" id="p-299"
id="p-299"
[000299] Activity profiles [0OO300] In previous experiments, it was noted that 18-MC HCI could pre—bind nAChFls in the absence of ACh and continued to accelerate the ACh-evoked current decay even after removal of drug. Such a profile indicates that the faster decay of ACh-evoked current is due to intrinsic changes in nAChR kinetics when 18-MC HCI is bound, not to onset of block induced by 18-MC binding (see FIGURE 19A-19B). 301. 301. 301. id="p-301" id="p-301" id="p-301" id="p-301" id="p-301" id="p-301" id="p-301"
id="p-301"
[000301] 30 uM concentrations of M4 and M5 metabolites were tested in similar manner to determine if they had similar activity. With respect to M4, the 30 uM concentration is approximately —times its lC50, comparable to the 10 uM 18-MC HCI shown. With respect to M5, the 30 uM 47 WO 2021/067549 PCT/US2020/053726 concentration is less than its |C50. As illustrated in FIGURES 20A-20D and summarized in TABLE 19, the M4 metabolite caused rapid block of ACh-evoked currents when co-applied, like 18-MC. Peak ACh- evoked currents were reduced by 68 i 2% when M4 was co-applied and by 86 i 2% when M4 was pre—applied and persisted during the ACh pulse. Unlike 18-MC, however, the M4 metabolite did not accelerate the ACh-evoked current decay after pre—exposure and removal. Rather, M4 pre- exposure abolished the peak of the ACh-evoked current and slowed its onset to the normal steady- state level. It is unclear from these experiments alone whether such behavior implies a mechanism of action that differs from that of 18-MC HCI. Rather, it can be explained entirely by the faster dissociation of M4 and lack of persistent inhibition. In either case, the results demonstrate that M4 can pre—bind to inhibit nAChRs in the absence or presence of agonist. Not surprisingly, given that M5 is comparably weak and dissociates rather quickly, no effect was seen after pre-incubation and removal of the M5 metabolite.
Table 19 18-MC and Metabolite Activity Profiles €o:x€s‘aE->AiX: 100 assays: 5a8~.=—24;~ Ezmtret "-4° ski}: + MA L 23 1" 24- x 4% 33$ 3: ES ......... ......... ............................................................... ............. .............. ............
............... ................................................................................... .............. ............. . ............................ Csn<:m:t.ratis;:.s as foilaws: AQE1 {E mist’), ivié [39 gm}, M5 (38 mt}. i82»*1C{i£}gs§%r§:}. ‘§* flames: was slew msst am 11:m~::§esensii:irs;ing {*::m1 131:: :3? taxes}. 302. 302. 302. id="p-302" id="p-302" id="p-302" id="p-302" id="p-302" id="p-302" id="p-302"
id="p-302"
[000302] The M4 metabolite pre—binds in the absence of ACh and blocks more completely when pre-applied. However M4 dissociates more quickly than 18-MC HCI such that solution jumps from M4 to ACh alone caused a slow onset response with no peak. The lower affinity M5 metabolite dissociates even faster, such that jumps from M5 to ACh alone had no effect on ACh-evoked currents. (Shown: 1 mM ACh; 30 uM M4, M5). [00O303] Additional information on the metabolites is shown in TABLE 20. 48 WO 2021/067549 PCT/US2020/053726 TABLE 20 Ori inal New Tn, Assi ned Molecular Theoretical Name Found m/Z Tn,g1in min ldenfity Formula m/2 Mass Difference" From mDa PPM Parent Parent 369.2164 8.82 8.6 18—Methoxycor0naridine C22H28N203 369.2178 -1.4 -3.8 -0.0014 Demethylation + M2 353.1858 5.46 5.23 Desaturation C21H24N203 353.1865 -0.7 -2.0 -16.0320 M3 355.2014 6.80 6.42 Demethylation C211-l26N203 355.2021 -0.7 -2.0 -14.0164 M4 367.2027 8.60 8.40 Desaturation C22H26N203 367.2021 0.6 1.6 -2.0151 M5 369.1816 7.52 7.31 2—Ethoxy|toAc1d C211-124N204 369.1814 0.2 0.5 -0.0362 Hydroxylation + M8 383.1970 5.53 5.13 Desaturation C22H26N204 383.1971 -0.1 -0.3 13.9792 Hydroxylation + M9 383.1956 6.21 5.83 Desaturation C221-l26N204 383.1971 -1.5 -3.9 13.9778 Demethylation + Glucuronide M12 531.2336 5.00 4.54 Conjugation C27l—l34N209 531.2342 -0.6 -1.1 162.0158 Demethylation + Hydroxylation + P2 373.2114 6.59 6.20 Reduction C21H28N204 373.2127 -1.3 -3.5 3.9936 .7 Hydroxy|ation+ P5 383.1982 - 3 Desaturation C22H26N204 383.1971 1.1 2.9 13.9804 Hydroxylation + P7 387.2295 8.91 8.52 Reduction C22H30N204 387.2284 1.1 2.8 18.0117 Desaturation + Demethylation + Glucuronide P10 529.2192 3.33 3.13 Conjugation C27H32N209 529.2186 0.6 1.1 160.0014 a Mass Difference represents the difference between m/z Found and Theoretical m/2 in both mil|iDalton (mDa) and parts per million (PPM). The difference of the Found m/2 from the Theoretical m/2 for the parent molecule is also reported.
[OOO304] Chemical names for several of the metabolites are as follows: 305. 305. 305. id="p-305" id="p-305" id="p-305" id="p-305" id="p-305" id="p-305" id="p-305"
id="p-305"
[000305] M2: methy|7-(2-hydroxyethyl)-7,8,9,10-tetrahydro-5H-6,9- methanopyrido[1',2‘:1,2]azepino[4,5-b]indole-6(6aH)—carboxy|ate 306. 306. 306. id="p-306" id="p-306" id="p-306" id="p-306" id="p-306" id="p-306" id="p-306"
id="p-306"
[000306] M3: methy|7-(2-hydroxyethyl)-7,8,9,10,12,13-hexahydro-5H-6,9- methanopyrido[1',2‘:1,2]azepino[4,5-b]indo|e-6(6aH)-carboxylate [00O307] M4: methy|7-(2-methoxyethyl)-7,8,9,10-tetrahydro-5H-6,9- methanopyrido[1',2':1,2]azepino[4,5-b]indole-6(6aH)-carboxylate [00O308] M5: 2—(6—(methoxycarbony|)—6,6a,7,8,9,10,12,13—octahydro—5H-6,9- methanopyrido[1',2‘:1,2]azepino[4,5-b]indo|-7-y|)acetic acid 309. 309. 309. id="p-309" id="p-309" id="p-309" id="p-309" id="p-309" id="p-309" id="p-309"
id="p-309"
[000309] M8: methyl 2-hydroxy-7-(2-methoxyethyl)-7,8,9,10-tetrahydro-5H-6,9- methanopyrido[1',2‘:1,2]azepino[4,5—b]indo|e-6(6aH)—carboxy|ate [0OO310] M12: (2S,3S,4S,5R,6R)—3,4,5—trihydroxy—6—(2—(6—(methoxycarbonyl)-6,6a,7,8,9,1 0,12,13- octahydro-5H-6,9-methanopyrido[1',2‘:1,2]azepino[4,5-b]indol-7-yl)ethoxy)tetrahydro-2H-pyran-2- 49 WO 2021/067549 PCT/US2020/053726 carboxylic acid 311. 311. 311. id="p-311" id="p-311" id="p-311" id="p-311" id="p-311" id="p-311" id="p-311"
id="p-311"
[000311] P10: (2S,3S,4S,5 Fl,6Fl‘)-3,4,5-trihydroxy-6-(2-(6-(methoxycarbonyl)-6,6a,7,8,9,10- hexahydro-5H-6,9-methanopyrido[1',2':1,2]azepino[4,5-b]indol-7-yl)ethoxy)tetrahydro-2H-pyran-2- carboxylic acid 312. 312. 312. id="p-312" id="p-312" id="p-312" id="p-312" id="p-312" id="p-312" id="p-312"
id="p-312"
[000312] CONCLUSIONS 313. 313. 313. id="p-313" id="p-313" id="p-313" id="p-313" id="p-313" id="p-313" id="p-313"
id="p-313"
[000313] Two major metabolites of 18—MC HCI, M4 and M5 (shown in FIGURES 21A and 21B), were tested in HEK 293 cells co-transfected with rat C13 and [34 subunit cDNAs. Both metabolites inhibited ACh-evoked currents with |C50 values of 2.6 uM for M4 and 57 uM for M5. These values are approximately 3.5- and 76-fold less potent, respectively, than the parent 18—MC HCI. The kinetics rates for M4 at 30 uM were kon 4.5 sec-1, koff = 2.5 sec-1 and the persistent inhibition at 1 sec after removal was 21 i 3%. The kinetic rates for M5 at 30 pM were kon 2.2 sec-1, koff = 6.2 sec-1 and the persistent inhibition at 1 sec after removal was 2 1 2%. 314. 314. 314. id="p-314" id="p-314" id="p-314" id="p-314" id="p-314" id="p-314" id="p-314"
id="p-314"
[000314] The activity profiles are generally consistent with M4 and M5 retaining some activity of 18- MC HCI, albeit with much reduced potency. The only phenotypic difference noted was the slow onset to steady—state of ACh-evoked currents following removal of M4 compared to 18—MC HCI, but this difference is entirely consistent with its faster dissociation from the receptor. 315. 315. 315. id="p-315" id="p-315" id="p-315" id="p-315" id="p-315" id="p-315" id="p-315"
id="p-315"
[000315] EXAMPLE 8 [0OO316] The purpose of the present study was to evaluate the effects of 18—MC HCI on lever pressing rates in rats maintained by intracranial self-stimulation (ICSS) using a frequency-rate procedure. Doses of 18—MC HCI (10, 40, 56 mg/kg) and vehicle (0.01 M NaH2PO4 in sterile water) were tested. Compared to vehicle, 18—MC HCI did not affect frequency-rate curves of ICSS, the estimated frequency that supports half-maximal responding (M50), nor threshold responding (T0).
Behavioral effects (loss of righting reflex, ataxia, ptosis) were observed in rats treated with all doses of 18—MC HCI approximately 5 minutes after injection, but rats appeared to have recovered prior to the start of the operant session (45 minutes after 18—MC HCI administration). Overall, these data suggest that 18—MC HCI does not alter responding reinforced by medial forebrain bundle stimulation under these conditions. 317. 317. 317. id="p-317" id="p-317" id="p-317" id="p-317" id="p-317" id="p-317" id="p-317"
id="p-317"
[000317] Background 318. 318. 318. id="p-318" id="p-318" id="p-318" id="p-318" id="p-318" id="p-318" id="p-318"
id="p-318"
[000318] ICSS involving electrical stimulation of the medial forebrain bundle is thought to result in activation of myelinated neurons that engage dopaminergic dendrites or cell bodies of the VTA and substantia nigra that subsequently send efferent, ascending projections throughout the mesocorticolimbic system. Drugs of abuse, such as nicotine, amphetamine, and the opiates generally enhance ICSS by reducing the threshold frequency or intensity that supports this behavior and this effect is hypothesized to correlate with their abuse-related effects. Conversely, drugs that produce 50 WO 2021/067549 PCT/US2020/053726 anhedonia or dysphoria, such as the neuroleptics, lithium, or K-opioid agonists, generally increase the threshold frequency or intensity that supports this behavior. 319. 319. 319. id="p-319" id="p-319" id="p-319" id="p-319" id="p-319" id="p-319" id="p-319"
id="p-319"
[000319] The present study evaluated 18-MC HCI for its ability to alter ICSS. Accordingly, rats were tested with vehicle, then 18-MC HCI (10, 40, and 56 mg/kg) given in a semi—randomized order, and once again tested with vehicle to assess stability over time. 320. 320. 320. id="p-320" id="p-320" id="p-320" id="p-320" id="p-320" id="p-320" id="p-320"
id="p-320"
[000320] Methods [00O321] Subiects 322. 322. 322. id="p-322" id="p-322" id="p-322" id="p-322" id="p-322" id="p-322" id="p-322"
id="p-322"
[000322] Eleven adult experimentally naive male Sprague-Dawley rats (Harlan, Indianapolis, IN) were individually housed in a temperature-controlled (20—22°C) AAALAC-accredited facility in which they had restricted access to food (7012 Teklad LM—485 Mouse/Rat Sterilizable Diet; Harlan, Indianapolis, IN) for maintaining a weight range of 380-420 g, and ad libitum access to water. The rats were maintained on a 12 hour/12 hour light—dark cycle (0600-1800 lights on) for the duration of the experiment, and they were trained and tested during the light segment of this cycle. Rats (360- 420 g at time of surgery) were anesthetized via isoflurane inhalation (~3%) and an electrode was implanted into the medial forebrain bundle according to stereotaxic coordinates, anteroposterior: -2.8 mm from bregma, lateral: 1.7 mm from the midline, ventrodorsalz -7.8 mm from skull (Paxinos & Watson, 2007). 323. 323. 323. id="p-323" id="p-323" id="p-323" id="p-323" id="p-323" id="p-323" id="p-323"
id="p-323"
[000323] Apparatus 324. 324. 324. id="p-324" id="p-324" id="p-324" id="p-324" id="p-324" id="p-324" id="p-324"
id="p-324"
[000324] Experimental sessions were conducted in standard operant conditioning chambers enclosed in sound-attenuating cubicles each with a ventilation fan and featured two retractable levers on the front intelligence panel, a stimulus lamp above each lever, and a 5-W house light (Med Associates, St. Albans, VT). A counterbalanced tether (Plastics One, Roanoke, VA) connected the electrode to an ICSS stimulator (product number PHM-152/2, Med Associates, St. Albans, VT), allowing free movement within the operant chamber. 325. 325. 325. id="p-325" id="p-325" id="p-325" id="p-325" id="p-325" id="p-325" id="p-325"
id="p-325"
[000325] Procedure 326. 326. 326. id="p-326" id="p-326" id="p-326" id="p-326" id="p-326" id="p-326" id="p-326"
id="p-326"
[000326] One week after surgery, the rats began fixed ratio 1 (FR1) self-stimulation training.
Initially, both left and right levers were extended, the house light illuminated, and each press of the right—side lever (i.e., FR1) resulted in the delivery of stimulation (100 uA, 158 Hz). Responses on the left lever were without programmed consequences. During the duration of the delivery of stimulation (500 ms), the house light was extinguished and the cue lights above each lever flashed at 3 Hz.
Current intensity was individually adjusted when necessary to maintain stable maximal rates of behavior (>40 responses/min) at the highest frequency. This intensity level was held constant for the remainder of the experiment. 327. 327. 327. id="p-327" id="p-327" id="p-327" id="p-327" id="p-327" id="p-327" id="p-327"
id="p-327"
[000327] The frequency-rate procedure (modified from Carlezon & Wise, 1996) consisted of 51 WO 2021/067549 PCT/US2020/053726 multiple (see below) components, each composed of 10, 1-minute FR 1 reinforcement periods.
During each 1-minute reinforcement period, a single, scheduled frequency was available for delivery contingent upon FR 1 responding. Frequencies were progressively decreased in 0.05 log-increments from 158-56 Hz (i.e. 2.2—1.75 log Hz) during each component. Each 1-minute reinforcement period was preceded by a 5—second sample period during which five non—contingent stimulations were delivered at the scheduled stimulation frequency. Each response period was followed by a 5—second timeout (TO) period during which the house light was extinguished and ICSS was unavailable. Rats were trained daily (M-F) using the described procedure. Training sessions were conducted in the morning and consisted of three consecutive components. Once stable behavior was established, as demonstrated by < 10% variation in threshold (i.e. theta 0; T0) and M50 (see Data Analysis) for three consecutive sessions, animals began testing, and baseline stability was monitored throughout the course of the experiment. Threshold (T0) is the theoretical frequency at which the linear portion of the frequency-rate curve intersects with the abscissa (i.e., zero responses). M50 is the estimated frequency that supports half-maximal responding. 328. 328. 328. id="p-328" id="p-328" id="p-328" id="p-328" id="p-328" id="p-328" id="p-328"
id="p-328"
[000328] On test days, two ICSS experimental sessions were conducted. During the baseline session, each rat was tested during three consecutive components identical to training days. After completing this baseline determination, rats were returned to their home cages and then received an i.p. injection of either 18-MC HCI (10, 40, or 56 mg/kg) or vehicle [0.01M NaH2PO4, Sigma Cat # S0751, Sigma Aldrich, St. Louis, MO] 45 minutes prior to the test session. Rats were returned to operant chambers for the test session that consisted of two consecutive components (i.e., two complete frequency sweeps). Doses of 18-MC HCI were determined according to a semi-randomized order. 329. 329. 329. id="p-329" id="p-329" id="p-329" id="p-329" id="p-329" id="p-329" id="p-329"
id="p-329"
[000329] Subjects were tested up to twice weekly (typically Tuesday and Friday), with a minimum of 72 hours between test sessions. Frequency-rate training sessions were conducted during the week on non-test days to maintain and monitor stability in frequency-rate responding, and to determine testing eligibility. Rats were required to meet stability criteria (< 10% variation in threshold and in the M50 from the last baseline test session) in order to be scheduled for testing. One to two frequency- rate training sessions were conducted between test sessions to assess behavioral stability. 330. 330. 330. id="p-330" id="p-330" id="p-330" id="p-330" id="p-330" id="p-330" id="p-330"
id="p-330"
[000330] Data Analysis [OOO331] Two rats were excluded from data analyses. One was excluded because of unstable baseline performance, and one was removed due to electrode patency, thus, the results included in this report are from nine rats. Results from the initial component during baseline sessions on test days were excluded from the data analysis as it has been shown that behavior is less stable during the first daily experimental component relative to subsequent components. Results obtained at each 52 WO 2021/067549 PCT/US2020/053726 frequency during each of the two subsequent baseline components were averaged to determine a baseline response rate for each frequency. Maximum control response rate (MCR) was then defined by the maximum baseline response rate that occurred across all frequencies during the baseline session. For subsequent data analyses, individual rat results during the baseline and test sessions were then normalized to a rat's MCR to produce percent maximum control rate (%MCR) scores by dividing the mean number of responses obtained at each frequency by the rat's MCR as determined during the associated (i.e., the same day's) baseline session, and then finally multiplying this quotient by 100, separately for the baseline and test sessions. 332. 332. 332. id="p-332" id="p-332" id="p-332" id="p-332" id="p-332" id="p-332" id="p-332"
id="p-332"
[000332] Frequency-rate response data were analyzed using two-way (treatment x frequency) repeated measures ANOVAs, followed by Holm-Sidak multiple comparisons tests to identify treatment-related differences in responding at each frequency. For all frequency-rate curves, vehicle served as the comparison condition. Parallel leftward shifts in the frequency-rate curve may be indicative of reward facilitation, and parallel rightward shifts in the frequency-rate curve can be indicative of reward attenuation. Upward (rate increasing) or downward (rate decreasing) shifts in the frequency-rate curve at maximum response rates may be indicative of nonspecific motoric effects. [00O333] In addition to frequency-rate response curves, additional summary dependent measures were calculated and analyzed. Threshold (T0) is the theoretical frequency at which the linear portion of the frequency-rate curve intersects with the abscissa (i.e., zero responses). M50 is the estimated frequency that supports half-maximal responding (i.e. 50%). Log transformations of frequency-rate curves were calculated using linear regression analysis to determine the T0 and M50 for each animal at each dose tested. TO and M50 log frequency values were determined for each baseline and corresponding test session and analyzed using one-way repeated measures ANOVA for each condition (baseline and test), and multiple comparisons were made using Fisher’s LSD test to compare all 18-MC HCI doses to vehicle control. In addition, TO and M50 raw frequencies after drug administration were normalized to baseline values (percent baseline TO and M50), analyzed using repeated measures ANOVA and multiple comparisons were conducted using Fisher’s LSD test. All statistical tests were conducted using microcomputer software (Prism 6, GraphPad Software, lnc., San Diego, CA), and all types of comparisons were considered statistically significant if p<0.05. 334. 334. 334. id="p-334" id="p-334" id="p-334" id="p-334" id="p-334" id="p-334" id="p-334"
id="p-334"
[000334] Observational Notes [00O335] Visual signs of impairment/intoxication, including loss of righting reflex, ataxia, and ptosis were observed in rats treated with the dose of 18-MC HCI. These effects were prominent approximately 5 minutes following drug administration and were not observed in vehicle-treated rats.
After the 45 minutes pretreatment time lapsed, subjects appeared normal in the home cage and upon handfing. 53 WO 2021/067549 PCT/US2020/053726 336. 336. 336. id="p-336" id="p-336" id="p-336" id="p-336" id="p-336" id="p-336" id="p-336"
id="p-336"
[000336] Effects of 18-MC HCI on freauencv-rate ICSS 337. 337. 337. id="p-337" id="p-337" id="p-337" id="p-337" id="p-337" id="p-337" id="p-337"
id="p-337"
[000337] Frequency-rate results with 18-MC HCI (10-56 mg/kg) and vehicle are presented in FIGURE 22. Frequency-rate response curve for the effects of 18-MC HCI (10, 40, 56 mg/kg) or vehicle (0.01M NaH2PO4). Values represent the mean normalized response rate (% of maximum control responding) across 10 frequency presentations (1.75 — 2.20 log/Hz) of 9 rats. Error bars are omitted for clarity. There was a significant main effect of frequency [F(9, 72)=106.5, p<0.0001], but no main effect of 18-MC HCI treatment on ICSS [F(3, 24)=0.42, p>0.05], and no interaction [F(27, 216)=0.75, p>0.05]. Specifically, no tested dose of 18-MC HCI (10-56 mg/kg) affected the ICSS frequency-rate curve. Maximal response rates were not altered during 18-MC HCI testing, suggesting that it does not produce generalized motor impairment within the time frame tested. 338. 338. 338. id="p-338" id="p-338" id="p-338" id="p-338" id="p-338" id="p-338" id="p-338"
id="p-338"
[000338] The effects of 18-MC HCI on T0 and M50 levels for all test conditions are presented on FIGURES 23A-23B and TABLES 20-21. Effects of 18-MC HCI on percent baseline T0 and M50 are shown. Values represent means (+ SEM) of calculated T0 (top panel) or M50 (bottom panel) normalized to baseline in 9 rats. There were no significant differences compared to vehicle. When normalized to percent baseline, T0 and M50 were analyzed as separate one—way repeated measures ANOVAs (FIGURES 23A-23B). Analysis of T0 data (top panel) revealed there was not a main effect of 18-MC HCI treatment [F(3,24)=0.59, p>0.05]. Similarly, analysis of M50 data (bottom panel) revealed there was not a main effect of drug treatment [F(3,24)=0.24, p>.05]. Log frequency values for 18-MC HCI and baselines are displayed on TABLES 20 and 21 and did not differ from vehicle values. importantly, baseline T0’s and M50’s did not significantly vary during the course of the study (TABLES 20-21). Overall, results from these analyses were consistent with findings from the rate- frequency curve analysis, demonstrating that 18-MC HCI does not alter ICSS under the testing parameters. Given the observation that all doses of 18-MC HCI tested produced a marked alteration in behavior prior to the test sessions, testing may not have occurred within the period of peak behavioral activity. A more thorough characterization of 18-MC HCI, if warranted, would include assessment of 18-MC HCI following shorter pretreatment times.
TABLE 21 Th|‘eSh°|d (To) Baseline Test N VEH 1.81 (0.01) 1.81 (0.02) 9 mgflg 33,313 1.81 (0.02) 1.80 (0.03) 9 40 mgfig 33,313 1.83 (0.02) 1.85 (0.03) 9 55 mgfig 33,313 1.82 (0.02) 1.85 (0.02) 9 339. 339. 339. id="p-339" id="p-339" id="p-339" id="p-339" id="p-339" id="p-339" id="p-339"
id="p-339"
[000339] TABLE 21 is a summary table of threshold log10 frequency values (T0) in rats tested with 18-MC HCI (10-56 mg/kg) or vehicle. There were no significant differences in T0 values compared to the VEH condition using Fisher’s LSD multiple comparison test. Data represent the mean T0 54 WO 2021/067549 PCT/US2020/053726 frequency (log/Hz) + SEM of 9 rats.
TABLE 22 M50 Baseline Test N VEH 1.95 (0.01) 1.94 (0.01) 9 mg/kg 33,313 1.95 (0.01) 1.94 (0.02) 9 40 mgflg 33,313 1.97 (0.02) 1.95 (0.02) 9 56 mgfig 33,313 1.95 (0.01) 1.95 (0.02) 9 [00O340] TABLE 22 is a summary table of |og1O frequency values that sustained half-maximal responding (M50) in rats tested with 18—MC HCI (10-56 mg/kg) or vehicle. There were no significant differences in M50 values compared to the VEH condition using Fisher’s LSD multiple comparison test. Data represent the mean M50 frequency (log/Hz) + SEM of 9 rats. 341. 341. 341. id="p-341" id="p-341" id="p-341" id="p-341" id="p-341" id="p-341" id="p-341"
id="p-341"
[000341] Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. 342. 342. 342. id="p-342" id="p-342" id="p-342" id="p-342" id="p-342" id="p-342" id="p-342"
id="p-342"
[000342] The invention has been described in an illustrative manner, and it is to be understood that the terminology, which has been used is intended to be in the nature of words of description rather than of limitation. 343. 343. 343. id="p-343" id="p-343" id="p-343" id="p-343" id="p-343" id="p-343" id="p-343"
id="p-343"
[000343] Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described. 55 ._o_._§m_.___._u< 02.3 mg. .23 M." + w m N m m .. ... 8: 4.: no _ _o.naoo 1 92:3.’ 9223.. 828 .. 532 ._2._.__._.__ 4/ us. .5 .9 + e. + &. .§..._a._.__ . an 2.: us. 8 ¢ r _ :m> .0. sue. 02.3 ?: .9:mEV 0.2-3 0.? o.m O.N o.w 0:_moo0+ O :0 .mzm>>lO|.ON W M * ow m .0... o I00 O H om 0 ow %m / oor omr e «I00 Z w #50: .os_.2 9.5:. e8 >__2..
N #50: :23 _w>w_ mEmm_Q _U_._ 02.2 S —. $0 6 -- -2: (OUHOSECI %) U0!1B.l1S!U!ll.lpB-]|9S 9U!EDO3 9U!|959Q °/o m #50: E35. once _u_._ 22-3 _2o 82 ooh oomoow oom OON OOH E8 om ow om 3o£o:$.m+mn_oH-u> I m m_ m 3 0 _ n_ .5... _9=m_5 6... us:: 3 o 888 Sn .5 b ¥¥ ¥»% ycm ynyn OH 2 om mm |@ .2: 2 9.0 N 32$ -c~.
(W11) uop,e.I1ua:>uo:u 3w-81: eulsegd 3U!|959q J0 °/o OH #50: amsc__5m:_> S mE3o_u_ om; om, 8 o co. (was -/+) sosszud .IaAo1 amov .** m E _ H E d 3 mco_...3c_ OENUOU Oz mco_m3c_ 0C_nUOU J m w m ~ H 3 3 2 2 S S m w > m m ¢ m w H % SE to ta be be be >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 >3 U — h D h - h h - - — - h h h I - h I > C 1 , 0 \ . .. . W . .— 2 \ 4» Ma .3 . . I w _8.8.ma¢s_é IoI.oomm 8.mo=ma.2o_fi> I I m m_ m 3 O _ u_ :23 .26. «Emma .01 os_-3 2: 2 F rd 3... :5... * f 1 ,3 3 .n.. ...u._ .3>zzn4.. . on cé .:_c..§znlu guy/3>1fi\np°o) suo]sn;u] auuzoog nu: 2221! . R u : n : : : u u : u u : u nu ucow (9U!|9S2C| %) l.l0!l9.lJS!U!l1lpE-j|9S 3U!9303 O -2: 2 9.0 m 393 2 #50: A95 oE_._. 2: 2: _ no _o..=:oU El om- N8! l'°Nl ! 8' Law) Ienuazoa awqwaw me .o._ «£4 ~..._ 5.
NH #50: SEES cozmbcmocoo ..9 .9 we v I O I I C) LO -oo. 3 U5 q Emgm (%) U0!1!q!l-IUI 95819/\v n. 03.5 m_n.a_-...< acsomv 25...
N 34.5 n1.n_!.¢ U: 0.2-». om. mam... SN #8. .! 9:»... 2 .¢. _ ...a.... ._e..=.< Va 539: 2 9.0 m 52¢, _au"asc8 uo8_ (wdq) an}; 1.12:}; .6 -C -C .6 7» I. I. I. I. er .5» -C .I 0 6 oo L 9 - — - - - - - - .
C. n Eaoz. oE_._.
HHUH "mu. m 6: 02.2 mime SN a. 8. .1.
CM- mi»... 2 .0. 6 8 L 9 g v Co Z In » m n m . n n _ n m 95.5 n_a»_!.< N 3!... n7n.:.< — 03.5 n_nn_ae< 2 £59: 2 9.0 m 52m, $8 (fimuux) a.mssaJd poo|g :»;1o1sKs .0: USTM2 om_ w .a..o::._..P H N... U H N 6 8 L 9 C. 7 .9. Z .| _ . _ _ _ _ _ _ . _ . _ _ m 03.5 ._.......< _ W m 3 £59: H 3!: n1.m_!.< — onus: n_nh—!.< 2 9.0 A 32¢, I om.
.. SN (3[-{UJl.lJ)9.1nSSaJd poo|g onoasegq cane: com on" can on _ _ _ . _ _ _ .
I Illlllll I W: :6.- Vz EB...
NZ 1?- oz...» IOI oE.._. m> coflobcouc cu S... nmjbu) uoneuuaauoa :23 Ban. 2: 2 — (%) asuodsaa mmfimxaoz _ . I. m 22 2:8 vs. 2:3 V2 .23 vs. 2.: :U< 1.o< 18¢ ...o< 1.3. m 22 RE 3 9.0 a $23 com #50: mz ._U< , , _ , A,¥ —rqw+ 2 1,1 I J .
AN I A | 92 E2 E2 ._U< —_U< :U< uom Ego: mom MEG: mag #50: <3 #50: ms. xN_ 9.6 I I 05:: M 02.2 2 9.0 OH 393 EN 550: Z mi u_§_.im 3 9.0 Ha 52$ N_+o+| OHM 550: \o xo $1 /0 Z z_ NIQ- "EN 550: \o \o I fo- /o>\fl_ z z NIQ- NIO- 2 .5 NH 523 EN 550: \o \o éww /o z 2 , QHN $50: UHN $50: IO OI \O \O _._O H o /o _ N Z O\ IO- OI \O \O I O+ / Z 2 _ 2 .5 ma 52$ QN $50: _HN $50: mm 550: >o:m:cm:u_ mo._ m~.~ ~.~ mtm fin mod o.~ mm; m.— 3.. mg mp; NF _ _ _ _ _ _ _ _ _ _ _ _ -o % W B X -3 w n w 0 0 U .I_.
In 0 H 9 .II 3 .¢,F.? "E: 9:9: mm 4 -2: mS.$ "E: 35:. 3 W mF.$ "E: 9:9: 93 .0 _._m_> U. 2 .5 vfi $23 :_._ .9:m:: mmoo .c.tc...c..c. n_n_»< om ow o_. _._m_> . _ nu _ o :3 :3 % ® 53% S 9 m 9 w C._ 0 -o_._. -om_. :_._ .9:m:: mmoo .c._.c.;c..c. n_n_»< om ow o_. _._m_> _ _ __ . o :3 :3 % .218 B S 9 m 9 I. 0 -o_._. -om_ m_mN $50: 2 .5 3 $23 WO 2021/067549 PCT/US2020/053726
Claims (58)
1. A composition for treating substance use disorders comprising an effective amount of 18- Methoxycoronaridine salt (18—MC) in a pharmaceutical carrier.
2. The composition of claim 1, wherein said composition is formulated in an oral dose.
3. The composition of claim 1, wherein said composition is a hydrochloride salt.
4. A method of treating substance use disorders, including the steps of: administering an effective amount of 18—Methoxycoronaridine salt (18—MC) in a pharmaceutical carrier to an individual; and preventing substance abuse in the individual.
5. The method of claim 4, wherein the substance is chosen from the group consisting of cocaine, nicotine, opiates, alcohol, morphine, and methamphetamine.
6. The method of claim 4, wherein the individual is a human.
7. The method of claim 4, wherein said preventing step is further defined as reducing reinforcing and rewarding effects of the substance.
8. The method of claim 4, wherein said administering step is performed orally.
9. The method of claim 4, wherein the salt is a hydrochloride salt.
10. The method of claim 4, wherein said administering step is further defined as administering 0.01-10 mg/kg of 18-MC.
11. The method of claim 10, wherein said administering step is further defined as administering 20 mg or less per day of 18-MC.
12. The method of claim 4, wherein 18—MC administered follows a mu|tip|e—compartment model and a half-life is about 48 hours.
13. The method of claim 4, further including the step of blocking oi3[34 nicotinic receptors in the habenulo—interpeduncular pathway and the basolateral amygdala.
14. The method of claim 4, further including the step of inhibiting enzymes CYP2C9, CYP2C19, 56 WO 2021/067549 PCT/US2020/053726 CYP2C8, CYP2E1, and CYP3A4.
15. A method of preventing addictive behavior in an individual, including the steps of: administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual; and preventing addictive behavior in the individual.
16. The method of claim 15, wherein the salt is a hydrochloride salt.
17. The method of claim 15, wherein the substance is chosen from the group consisting of cocaine, nicotine, opiates, alcohol, morphine, and methamphetamine.
18. The method of claim 15, wherein the individual is a human.
19. The method of claim 15, wherein said preventing step is further defined as reducing reinforcing and rewarding effects of the substance.
20. The method of claim 15, wherein said administering step is performed orally.
21. The method of claim 15, wherein said administering step is further defined as administering 0.01-10 mg/kg of 18-MC.
22. The method of claim 21, wherein said administering step is further defined as administering 20 mg or less per day of 18-MC.
23. The method of claim 15, wherein 18-MC administered follows a mu|tip|e—compartment model and a half—life is about 48 hours.
24. The method of claim 15, further including the step of blocking d3B4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala.
25. The method of claim 15, further including the step of inhibiting enzymes CYP2C9, CYP2C19, CYP2C8, CYP2E1, and CYP3A4.
26. A method of preventing craving in an individual, including the steps of: administering an effective amount of 18-Methoxycoronaridine salt (18—MC) in a pharmaceutical carrier to an individual; and preventing craving in the individual. 57 WO 2021/067549 PCT/US2020/053726
27. The method of claim 26, wherein the salt is a hydrochloride salt.
28. The method of claim 26, wherein the substance is chosen from the group consisting of cocaine, nicotine, opiates, alcohol, morphine, and methamphetamine.
29. The method of claim 26, wherein the individual is a human.
30. The method of claim 26, wherein said preventing step is further defined as reducing reinforcing and rewarding effects of the substance.
31. The method of claim 26, wherein said administering step is performed orally.
32. The method of claim 26, wherein said administering step is further defined as administering 0.01-10 mg/kg of 18-MC.
33. The method of claim 32, wherein said administering step is further defined as administering 20 mg or less per day of 18—MC.
34. The method of claim 26, wherein 18-MC administered follows a multiple-compartment model and a half-life is about 48 hours.
35. The method of claim 26, further including the step of blocking C1364 nicotinic receptors in the habenu|o—interpeduncu|ar pathway and the basolateral amygdala.
36. The method of claim 26, further including the step of inhibiting enzymes CYP2C9, CYP2C19, CYP2C8, CYP2E1, and CYP3A4.
37. A composition comprising a metabolite of 18-MC salt.
38. The composition of claim 37, wherein said metabolite is chosen from the group consisting of M1, M2, M3, M4, M5, M6, M7, M8, M9, P1, P2, P3, and P10 and wherein the salt is a hydrochloride salt.
39. The composition of claim 37, wherein said metabolite is M4 or M5.
40. A method of treating substance use disorders including the steps of: administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual; and preventing substance abuse in the individual. 58 WO 2021/067549 PCT/US2020/053726
41. The method of claim 40, wherein the metabolite is chosen from the group consisting of M1, M2, M3, M4, M5, M6, M7, M8, M9, P1, P2, P3, and P10 and wherein the salt is a hydrochloride salt.
42. The method of claim 40, wherein the metabolite is M4 or M5.
43. The method of claim 40, wherein the substance is chosen from the group consisting of cocaine, nicotine, opiates, alcohol, morphine, and methamphetamine.
44. The method of claim 40, wherein the individual is a human.
45. The method of claim 40, wherein said preventing step is further defined as reducing reinforcing and rewarding effects of the substance.
46. The method of claim 40, wherein said administering step is performed orally.
47. The method of claim 40, wherein said administering step is further defined as administering 0.01 -1 0 mg/kg of a metabolite of 18—MC.
48. The method of claim 47, wherein said administering step is further defined as administering 20 mg or less per day of a metabolite of 18-MC.
49. The method of claim 40, wherein a metabolite of 18-MC administered has a half-life of about 48 hours.
50. The method of claim 40, further including the step of blocking C(3B4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala.
51. The method of claim 40, further including the step of inhibiting enzymes CYP2C9, CYP2C19, CYP2C8, CYP2E1, and CYP3A4.
52. A composition having the binding profile shown in Figure 2.
53. A composition having an action potential duration in rabbit cardiac Purkinje fibers shown in Figure 13.
54. A composition having a pharmacokinetic profiles of parent and a metabolite in human plasma shown in Figure 17.
55. A composition having an |C5o profiles of parent and one or more metabolites as shown in Figure 18E. 59 WO 2021/067549 PCT/US2020/053726
56. A composition having an a|pha3-beta4 nicotinic cholinergic receptor patch clamp assay profile as shown in Figures 19A and 19B.
57. A composition having a human metabolite a|pha3-beta4 nicotinic cholinergic receptor patch clamp assay profile as shown in any of Figures 20A, 20B, 20C and 20D.
58. A composition having an ICSS study profile in rats as shown in any of Figures 22, 23, or 24. 60
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962908754P | 2019-10-01 | 2019-10-01 | |
PCT/US2020/053726 WO2021067549A1 (en) | 2019-10-01 | 2020-10-01 | 18-mc for treatment of substance use disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL291890A true IL291890A (en) | 2022-06-01 |
Family
ID=75161488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL291890A IL291890A (en) | 2019-10-01 | 2020-10-01 | 18-mc for treatment of substance use disorders |
Country Status (9)
Country | Link |
---|---|
US (2) | US11596638B2 (en) |
EP (1) | EP4037689A4 (en) |
JP (1) | JP2022552162A (en) |
KR (1) | KR20220074908A (en) |
CN (1) | CN114786677A (en) |
AU (1) | AU2020357951B2 (en) |
CA (1) | CA3156514A1 (en) |
IL (1) | IL291890A (en) |
WO (1) | WO2021067549A1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6780871B2 (en) | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
US20150051192A1 (en) | 2012-03-27 | 2015-02-19 | Albany Medical College | Blocking of cue-induced drug reinstatement |
WO2015095644A1 (en) * | 2013-12-20 | 2015-06-25 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
CA2978537C (en) * | 2014-03-03 | 2023-10-24 | Demerx, Inc. | Therapeutic uses of ibogaine and related compounds |
US20150246055A1 (en) * | 2014-03-03 | 2015-09-03 | Demerx, Inc. | Methods for acute and long-term treatment of opioid and opioid-like drug addiction |
US20150258108A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods and compositions for reducing tolerance to opioid analgesics |
US20150258109A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Low dose administration of ibogaine for treating nicotine addiction and preventing relapse of nicotine use |
-
2020
- 2020-10-01 US US17/060,443 patent/US11596638B2/en active Active
- 2020-10-01 CN CN202080081807.6A patent/CN114786677A/en not_active Withdrawn
- 2020-10-01 JP JP2022520617A patent/JP2022552162A/en not_active Withdrawn
- 2020-10-01 CA CA3156514A patent/CA3156514A1/en active Pending
- 2020-10-01 WO PCT/US2020/053726 patent/WO2021067549A1/en unknown
- 2020-10-01 KR KR1020227014115A patent/KR20220074908A/en unknown
- 2020-10-01 EP EP20872214.0A patent/EP4037689A4/en not_active Withdrawn
- 2020-10-01 IL IL291890A patent/IL291890A/en unknown
- 2020-10-01 AU AU2020357951A patent/AU2020357951B2/en active Active
-
2023
- 2023-02-24 US US18/174,063 patent/US20230201217A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021067549A1 (en) | 2021-04-08 |
JP2022552162A (en) | 2022-12-15 |
US20210093643A1 (en) | 2021-04-01 |
CN114786677A (en) | 2022-07-22 |
KR20220074908A (en) | 2022-06-03 |
EP4037689A1 (en) | 2022-08-10 |
US11596638B2 (en) | 2023-03-07 |
AU2020357951B2 (en) | 2024-01-11 |
AU2020357951A1 (en) | 2022-05-12 |
CA3156514A1 (en) | 2021-04-08 |
EP4037689A4 (en) | 2023-07-12 |
US20230201217A1 (en) | 2023-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060040980A1 (en) | Ionophores as cancer chemotherapeutic agents | |
US5965571A (en) | Cholinesterase inhibitors for treatment of Parkinson's disease | |
IL278053B1 (en) | Peptide macrocycles against acinetobacter baumannii | |
EP4342465A2 (en) | Methods of treating hepatic encephalopathy | |
US20200113882A1 (en) | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions | |
JPH06507617A (en) | Treatment of fatigue syndrome | |
IL297912A (en) | Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics | |
JP2019513759A (en) | How to treat eye condition | |
US20050277626A1 (en) | Methods and compositions for treatment of nicotine dependence and dementias | |
IL291890A (en) | 18-mc for treatment of substance use disorders | |
AU2005207906B2 (en) | Preventive or therapeutic agent for diabetic maculopathy | |
US20230000799A1 (en) | Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy | |
AU2004216360B2 (en) | Pharmaceutical composition for treatment of drug dependence | |
Panikkar | Cocaine addiction: neurobiology and related current research in pharmacotherapy | |
EP2120937B1 (en) | A composition comprising (r)-spiro[l- azabicyclo[2.2.2]octane-3,2'(3'h) -furo[2,3 -b]pyridine (azd0328) and its use in the treatment of alzheimer's disease, adhd or cognitive dysfunction | |
Martin et al. | Pharmacology of drugs of abuse | |
US20180153872A1 (en) | Heteroaryl carbonitriles for the treatment of disease | |
KR20210124962A (en) | 3β-(benzyloxy)-17α-methyl-pregun-5-en-20-one for use in the treatment of cognitive impairment | |
Claytor | Pharmacological and behavioral characterization of the dopamine D3 receptor in preclinical models of cocaine abuse | |
Nir | Antiprotozoal drugs |